ࡱ> !a Nbjbj** UH=bH=bMdP(x p"p"p""""8"P% "\.Z4p4p4p4*J[Da$]p"nEx*Jnnp4p4Bozzzn| p4p"p4znzzD!0p4J~wo<8x0t5q5p00L5p"| cHgzi kccc%u\cccnnnn5cccccccccB :   Scottish Cancer Taskforce National Cancer Quality Steering Group Breast Cancer Clinical Quality Performance Indicators Engagement Document April 2019 Contents Page  TOC \o "1-2" \h \z \u  HYPERLINK \l "_Toc7510955" 1. National Cancer Quality Programme  PAGEREF _Toc7510955 \h 7  HYPERLINK \l "_Toc7510956" 1.1 Quality Assurance and Continuous Quality Improvement  PAGEREF _Toc7510956 \h 7  HYPERLINK \l "_Toc7510957" 2. Quality Performance Indicator (QPI) Development Process  PAGEREF _Toc7510957 \h 7  HYPERLINK \l "_Toc7510958" 3. QPI Formal Review Process  PAGEREF _Toc7510958 \h 8  HYPERLINK \l "_Toc7510959" 4. Format of the Quality Performance Indicators  PAGEREF _Toc7510959 \h 8  HYPERLINK \l "_Toc7510960" 5. Supporting Documentation  PAGEREF _Toc7510960 \h 9  HYPERLINK \l "_Toc7510961" 6. Quality Performance Indicators for Breast Cancer  PAGEREF _Toc7510961 \h 10  HYPERLINK \l "_Toc7510962" QPI 1: Multidisciplinary Team Meeting (MDT)  PAGEREF _Toc7510962 \h 10  HYPERLINK \l "_Toc7510963" QPI 2: Non-Operative Diagnosis  PAGEREF _Toc7510963 \h 10  HYPERLINK \l "_Toc7510964" QPI 3: Pre-Operative Assessment of Axilla  PAGEREF _Toc7510964 \h 10  HYPERLINK \l "_Toc7510965" QPI 4: Conservation Rate  PAGEREF _Toc7510965 \h 10  HYPERLINK \l "_Toc7510966" QPI 5: Surgical Margins  PAGEREF _Toc7510966 \h 11  HYPERLINK \l "_Toc7510967" QPI 6: Immediate Reconstruction Rate  PAGEREF _Toc7510967 \h 12  HYPERLINK \l "_Toc7510968" QPI 8: Minimising Hospital Stay Day Case Surgery  PAGEREF _Toc7510968 \h 14  HYPERLINK \l "_Toc7510969" QPI 9: HER2 Status for Decision Making  PAGEREF _Toc7510969 \h 16  HYPERLINK \l "_Toc7510970" QPI 10: Radiotherapy for Breast Conservation in Older Adults  PAGEREF _Toc7510970 \h 17  HYPERLINK \l "_Toc7510971" QPI 11: Adjuvant Chemotherapy  PAGEREF _Toc7510971 \h 18  HYPERLINK \l "_Toc7510972" QPI 13: Re-excision Rates  PAGEREF _Toc7510972 \h 20  HYPERLINK \l "_Toc7510973" QPI 14: Referral for Genetics Testing  PAGEREF _Toc7510973 \h 21  HYPERLINK \l "_Toc7510974" QPI 15: 30 Day Mortality following Chemotherapy  PAGEREF _Toc7510974 \h 23  HYPERLINK \l "_Toc7510975" QPI 16: Clinical Trial and Research Study Access  PAGEREF _Toc7510975 \h 24  HYPERLINK \l "_Toc7510976" QPI 17: Genomic Testing  PAGEREF _Toc7510976 \h 25  HYPERLINK \l "_Toc7510977" QPI 18: Neo-adjuvant Chemotherapy  PAGEREF _Toc7510977 \h 26  HYPERLINK \l "_Toc7510978" QPI 19: Deep Inspiratory Breath Hold (DIBH) Radiotherapy  PAGEREF _Toc7510978 \h 28  HYPERLINK \l "_Toc7510979" 7. Survival  PAGEREF _Toc7510979 \h 29  HYPERLINK \l "_Toc7510980" 8. Areas for Future Consideration  PAGEREF _Toc7510980 \h 29  HYPERLINK \l "_Toc7510981" 9. Governance and Scrutiny  PAGEREF _Toc7510981 \h 29  HYPERLINK \l "_Toc7510982" 9.1 National  PAGEREF _Toc7510982 \h 29  HYPERLINK \l "_Toc7510983" 9.2 Regional Regional Cancer Networks  PAGEREF _Toc7510983 \h 30  HYPERLINK \l "_Toc7510984" 9.3 Local NHS Boards  PAGEREF _Toc7510984 \h 30  HYPERLINK \l "_Toc7510985" 10. References  PAGEREF _Toc7510985 \h 31  HYPERLINK \l "_Toc7510986" 11. Appendices  PAGEREF _Toc7510986 \h 33  HYPERLINK \l "_Toc7510987" Appendix 1: QPI Development Process  PAGEREF _Toc7510987 \h 33  HYPERLINK \l "_Toc7510988" Appendix 2: Breast Cancer QPI Development Group Membership (2012)  PAGEREF _Toc7510988 \h 35  HYPERLINK \l "_Toc7510989" Appendix 3: Breast Cancer QPI Formal Review Group Membership (2016)  PAGEREF _Toc7510989 \h 37  HYPERLINK \l "_Toc7510990" Appendix 4: 2nd Cycle - Breast Cancer QPI Formal Review Group Membership (2018)  PAGEREF _Toc7510990 \h 38  HYPERLINK \l "_Toc7510991" Appendix 5: 3-Yearly National Governance Process and Improvement Framework for Cancer Care  PAGEREF _Toc7510991 \h 39  HYPERLINK \l "_Toc7510992" Appendix 6: Regional Annual Governance Process and Improvement Framework for Cancer Care  PAGEREF _Toc7510992 \h 40  HYPERLINK \l "_Toc7510993" Appendix 7: Glossary of Terms  PAGEREF _Toc7510993 \h 41  1. National Cancer Quality Programme Beating Cancer: Ambition and Action (2016)1 details a commitment to delivering the national cancer quality programme across NHSScotland, with a recognised need for national cancer QPIs to support a culture of continuous quality improvement. Addressing variation in the quality of cancer services is pivotal to delivering improvements in quality of care. This is best achieved if there is consensus and clear indicators for what good cancer care looks like. Small sets of cancer specific outcome focussed, evidence based indicators are in place for 18 different tumour types. These are underpinned by patient experience QPIs that are applicable to all, irrespective of tumour type. These QPIs ensure that activity is focused on those areas that are most important in terms of improving survival and individual care experience whilst reducing variation and supporting the most effective and efficient delivery of care for people with cancer. QPIs are kept under regular review and are responsive to changes in clinical practice and emerging evidence. A programme to review and update the QPIs in line with evolving evidence is in place as well as a robust mechanism by which additional QPIs will be developed over the coming years. 1.1 Quality Assurance and Continuous Quality Improvement The ultimate aim of the programme is to develop a framework, and foster a culture of, continuous quality improvement, whereby real time data is reviewed regularly at an individual Multi Disciplinary Team (MDT)/Unit level and findings actioned to deliver continual improvements in the quality of cancer care. This is underpinned and supported by a programme of regional and national comparative reporting and review. NHS Boards are required to report against QPIs as part of a mandatory, publicly reported, programme at a national level. A rolling programme of reporting is in place, with approximately three national tumour specific reports published annually. National reports include comparative reporting of performance against QPIs at MDT/Unit level across NHSScotland, trend analysis and survival. This approach helps to overcome existing issues relating to the reporting of small volumes in any one year. In the intervening years tumour specific QPIs are monitored on an annual basis through established Regional Cancer Network and local governance processes, with analysed data submitted to Information Services Division (ISD) for inclusion in subsequent national reports. This approach ensures that timely action is taken in response to any issues that may be identified through comparative reporting and systematic review. 2. Quality Performance Indicator (QPI) Development Process The QPI development process was designed to ensure that indicators are developed in an open, transparent and timely way. The development process can be found in appendix 1. The Breast Cancer QPI Development Group was convened in December 2010, chaired by Dr Jennifer Armstrong (Senior Medical Officer, Scottish Government). Membership of this group included clinical representatives drawn from the three regional cancer networks, Healthcare Improvement Scotland (formerly NHS Quality Improvement Scotland), Information Services Division (ISD) and patient/carer representatives. Membership of the development group can be found in appendix 2. 3. QPI Formal Review Process As part of the National Cancer Quality Programme a systematic national review process has been developed, whereby all tumour specific QPIs published are subject to formal review following 3 years analysis of comparative QPI data. Formal review of the Breast Cancer QPIs was undertaken for the first time in December 2015. A Formal Review Group was convened, chaired by Dr Hilary Dobson (Chair, National Cancer Quality Steering Group). Membership of this group included Clinical Leads from the three Regional Cancer Networks and can be found in appendix 3. The 2nd Cycle of Formal Review commenced in December 2018 following reporting of 6 years QPI data. This cycle of review is more selective and focussed on ensuring the ongoing clinical relevance of the QPIs. A Formal Review Group was convened in December 2018, with Mr Seamus Teahan, Consultant Urological Surgeon and Regional Lead Cancer Clinician, WoSCAN appointed as Clinical Advisor/Chair to the group. Membership of this group can be found in appendix 4. The formal review process is clinically driven with proposals for change sought from specialty specific representatives in each of the Regional Cancer Networks. The review builds on existing evidence using expert clinical opinion to identify where new evidence is available. Formal review meetings to further discuss proposals will be arranged where deemed necessary. During formal review QPIs may be archived and replaced with new QPIs. Triggers for doing so include significant change to clinical practice, targets being consistently met by all Boards, and publication of new evidence. Where QPIs have been archived, for those indicators which remain clinically relevant, data will continue to be collected to allow local / regional analysis of performance as required. Any new QPIs have been developed in line with the following criteria: Overall importance does the indicator address an area of clinical importance that would significantly impact on the quality and outcome of care delivered? Evidence based is the indicator based on high quality clinical evidence? Measurability is the indicator measurable i.e. are there explicit requirements for data measurement and are the required data items accessible and available for collection? 4. Format of the Quality Performance Indicators QPIs are designed to be clear and measurable, based on sound clinical evidence whilst also taking into account other recognised standards and guidelines. Each QPI has a short title which will be utilised in reports as well as a fuller description which explains exactly what the indicator is measuring. This is followed by a brief overview of the evidence base and rationale which explains why the development of this indicator was important. The measurability specifications are then detailed; these highlight how the indicator will actually be measured in practice to allow for comparison across NHSScotland. Finally a target is indicated, this dictates the level which each unit should be aiming to achieve against each indicator. In order to ensure that the chosen target levels are the most appropriate and drive continuous quality improvement as intended they are kept under review and revised as necessary, if further evidence or data becomes available. Rather than utilising multiple exclusions, a tolerance level has been built into the QPIs. It is very difficult to accurately measure patient choice, co-morbidities and patient fitness therefore target levels have been set to account for these factors. Further detail is noted within QPIs where there are other factors which influenced the target level. Where less than (<) target levels have been set the rationale has been detailed within the relevant QPI. All other target levels should be interpreted as greater than (>) levels. 5. Supporting Documentation A national minimum core dataset and a measurability specification document have been developed in parallel with the indicators to support the monitoring and reporting of Breast Cancer QPIs. These will be implemented for all patients diagnosed with breast cancer on, or after, 1st January 2019. 6. Quality Performance Indicators for Breast Cancer QPI 1: Multidisciplinary Team Meeting (MDT) Revisions:This QPI has been archived all regions / healthboards are consistently meeting and exceeding the 95% target (> 3 years) for patients with a newly diagnosed Breast Cancer who are discussed by a multidisciplinary team prior to definitive treatment.  QPI 2: Non-Operative Diagnosis Revisions:This QPI has been archived all regions / healthboards are consistently meeting and exceeding the 95% target (>3 years) for patients with breast cancer that have a non-operative histological diagnosis.  QPI 3: Pre-Operative Assessment of Axilla Revisions:This QPI has been archived all regions / healthboards consistently meeting and exceeding the following targets: 95% of patients who undergo assessment of the axilla by ultrasound prior to surgery; and 85% of patients with suspicious morphology who undergo FNA/core biopsy of the axilla before surgery.  QPI 4: Conservation Rate Revisions:This QPI has been archived all regions and healthboards are achieving and exceeding 90% target for patients with small breast cancers (20mm) undergoing breast conservation whenever appropriate. Data analysis shows that the majority of healthboards are also achieving >90% for tumours >30mm.  QPI 5: Surgical Margins Revisions:This QPI has been archived all regions / healthboards are consistently meeting and exceeding the 90% target (>3 years) for patients undergoing conservation surgery with final radial excision margins less than 1mm.  QPI 6: Immediate Reconstruction Rate QPI Title:Patients undergoing mastectomy for breast cancer should have access to timely immediate breast reconstruction. Description: Proportion of patients who undergo immediate breast reconstruction at the time of mastectomy for breast cancer, and within 6 weeks of treatment decision. Please note: The specifications of this QPI measure two distinct elements: Patients with breast cancer undergoing immediate breast reconstruction at the time of mastectomy; and Patients with breast cancer undergoing immediate breast reconstruction at the time of mastectomy, and within 6 weeks of treatment decision. Rationale and Evidence: Evidence suggests that breast reconstruction is not associated with an increase in the rate of local recurrence, nor does it affect the ability to detect recurrence, and it can yield psychological benefit. There may be good reasons for individual patients not to undergo immediate breast reconstruction but this indicator is intended to demonstrate that mastectomy patients have access to a reconstructive service2,3. Access to immediate breast reconstruction is very difficult to measure accurately therefore uptake is utilised within this QPI as a proxy for access. Although it will not provide an absolute measure of patient access to this procedure it will give an indication of access across NHS Boards and highlight any areas of variance which can then be further examined. Timeliness of immediate breast reconstruction is being reviewed as part of this QPI to ensure that there is no impact on quality of care for patients undergoing this treatment option. Specification (i): Numerator: Number of patients with breast cancer undergoing immediate breast reconstruction at the time of mastectomy. Denominator: All patients with breast cancer undergoing mastectomy. Exclusions: All patients with M1 disease. All male patients. Target:20% The tolerance within this target accounts for patient choice and fitness for treatment. Patient choice is a key factor in the number of patients who undergo immediate breast reconstruction at the time of mastectomy.  (continued overleaf) QPI 6: Immediate Reconstruction Rate..continued Specification (ii): Numerator: Number of patients with breast cancer undergoing immediate breast reconstruction at the time of mastectomy within 6 weeks of treatment decision. Denominator: All patients with breast cancer undergoing immediate reconstruction at the time of mastectomy. Exclusions: All patients with M1 disease. All male patients. Patients who undergo neoadjuvant chemotherapy. Target:90% The tolerance within this target is designed to account for situations where immediate breast reconstruction may be delayed due to factors patient choice and fitness for treatment.  Revision(s):Specification (i) target reduced from 25% to 20% due to the increase in conservation surgery now taking place. Specification (ii) added to assess timeliness of immediate breast reconstruction within 6 weeks of treatment decision.  QPI 8: Minimising Hospital Stay Day Case Surgery QPI Title:Patients should have the opportunity for day case / 23 hour)** breast surgery wherever appropriate. Description: Proportion of patients undergoing day case / 23 hour surgery for breast cancer. Please note: This QPI measures two distinct elements. Patients with breast cancer undergoing wide excision and / or an axillary sampling procedure as day case surgery; and Patients with breast cancer undergoing mastectomy (without reconstruction) with a maximum hospital stay of 1 night following their procedure. Rationale and Evidence: It has been shown that major breast surgery can be delivered safely as day case or one night stay in the majority of patients without compromising clinical quality, surgical outcomes, and patient experience4. Benefits of short stay following surgery include: reduction in re-admissions, reduction in complications, improved patient mobility and enhanced recovery5. **Within the measurement of this QPI, day case surgery is defined as those patients who are admitted and discharged on the same day as their procedure. 23 hour surgery is defined as surgery which includes a maximum of one night stay following their procedure. Specification (i): Numerator: Number of patients with breast cancer undergoing wide excision and/or axillary sampling procedure (sentinel node biopsy or 4 node sample) as day case surgery. Denominator: All patients with breast cancer undergoing wide excision and/or axillary sampling procedure (sentinel node biopsy or 4 node sample). Exclusions: All patients with breast cancer undergoing partial breast reconstruction. Specification (ii): Numerator: Number of patients with breast cancer undergoing mastectomy (without reconstruction) with a maximum hospital stay of 1 night following their procedure. Denominator: All patients with breast cancer undergoing mastectomy (without reconstruction). Exclusions: No exclusions  (continued overleaf) QPI 8: Minimising Hospital Stay Day Case / 23 hour Breast Surgery.continued Target:60% The tolerance within this target takes account of the fact that day case surgery may not be appropriate for all patients due to social circumstances, co-morbidities and/or the geographical area in which they live. It may not always be safe or practical for patients to go home immediately after surgery; this may therefore affect short-stay surgery rates across NHSScotland.  Please note: SMR01 data will be utilisedto support reporting and monitoring of this QPIrather than clinical audit. This willmaximise the use of data which are already collected and remove the need for any duplication of data collection. Standard reports will be specified and direct access given for each Board to run these reportsto ensurenationally consistent analysis and reporting. Revision(s):Specification (ii) added to measure the proportion of patients undergoing mastectomy (without reconstruction) as 23 hour surgery (maximum of one overnight stay following their procedure).  QPI 9: HER2 Status for Decision Making QPI Title:HER2 status should be available to inform treatment decision making. Description: Proportion of patients with invasive breast cancer for whom the HER2 status (as detected by immunohistochemistry (IHC) and/or FISH analysis) is reported within 2 weeks of core biopsy. Rationale and Evidence: HER2 status has a significant impact on survival and so has a significant influence on decisions on neoadjuvant and adjuvant treatment6. Delay in the availability of a HER2 result may lead to a delay in appropriate neoadjuvant or adjuvant therapy and make communication of a clear plan to the patient more difficult. At present HER2 testing is undertaken in all relevant cases; however the point of the patient pathway at which this takes place varies across NHS Scotland. The purpose of this indicator is to synchronise practice across Scotland by ensuring the availability of HER2 status in a timely manner to inform treatment decision making. Specifications: Numerator: Number of patients with invasive breast cancer for whom the HER2 status (as detected by immunohistochemistry (IHC) and/or FISH analysis) is reported within 2 weeks of core biopsy. Denominator: All patients with invasive breast cancer. Exclusions: Patients in whom no invasive carcinoma is present on core biopsy. Patients in whom insufficient disease is present on core biopsy. Target:90% The tolerance within this target is designed to account for situations where patients are unfit for treatment and for factors of patient choice. Please note: Varying evidence exists regarding the most appropriate target level; therefore this may need redefined in the future, to take account of new evidence or when baseline data becomes available.  Revisions:Exclusions added for: Patients in whom no invasive carcinoma is present on core biopsy; and Patients in whom insufficient disease is present on core biopsy. Target increased to 90%. QPI 10: Radiotherapy for Breast Conservation in Older Adults QPI Title:Radiotherapy use should be reduced in patients e" 70 years of age with T1 N0, ER-postive, HER2-negative and Grade I to II breast cancer where clinically appropriate. Description: Proportion of patients e" 70 years of age with T1 N0, ER-postive, HER2-negative and Grade I to II breast cancer undergoing conservation surgery with hormone therapy who do not receive radiotherapy. Rationale and Evidence: Measurement of this QPI reflects those early stage low risk patients identified within the PRIME II and CALGB 934 Breast Cancer Trials. Omission of radiotherapy may be considered given the minimal survival benefit gained in relation to the risk of toxicity and complications7,8,9. Studies have shown that in patients greater than 70 years of age with early stage low risk breast cancer, the omission of radiotherapy does not impact on distant recurrence or overall survival. There is a small reduction in local recurrence with the use of radiotherapy which should be taken into account when making decisions on treatment7,8,9. Treatment should not be selected solely according to age and decisions on appropriate treatment must take into account individual patient risk and quality of life. Specifications: Numerator: Number of patients e" 70 years with T1 N0, ER-postive, HER2-negative and Grade I to II breast cancer undergoing conservation surgery with hormone therapy who do not receive radiotherapy. Denominator: All patients e" 70 years with T1 N0, ER-postive, HER2-negative and Grade I to II breast cancer undergoing conservation surgery with hormone therapy. Exclusions: All patients with breast cancer taking part in clinical trials of radiotherapy treatment. Target:60% The tolerance within this target reflects factors of patient choice in choosing radiotherapy as a treatment option. It also accounts for those patients with lymphovascular invasion and high grade DCIS outwith the invasive tumour bed.  Revision(s):QPI changed to measure minimising radiotherapy treatment in T1 N0, ER-postive, HER2-negative and Grade I to II elderly patients with breast cancer.  QPI 11: Adjuvant Chemotherapy QPI Title:Patients with breast cancer should receive chemotherapy post operatively where it will provide a survival benefit for patients. Description: Proportion of patients with invasive breast cancer who have a e"5% overall survival benefit of chemotherapy treatment predicted at 10 years that undergo adjuvant chemotherapy. Please note: This QPI measures two distinct elements. (i)Patients with ER positive, HER2 negative breast cancer with a e"5% overall survival benefit of chemotherapy treatment predicted at 10 years and/or high risk genomic assay score.(ii)Patients with triple negative (ER negative, PR negative, HER2 negative) or HER2 positive breast cancer with e"5% overall survival benefit of chemotherapy treatment predicted at 10 years. Rationale and Evidence: Large randomised trials have confirmed that adjuvant systemic therapy improves relapse-free survival and overall survival10. Clinical trials have demonstrated that adjuvant drug treatments substantially reduce 5-year recurrence rates and 15-year mortality rates11. Success of treatment is based on a number of different factors including tumour size, grade and involvement of lymph nodes. Prognostic tools such as PREDICT assist clinicians and patients to make informed decisions on appropriate treatment by predicting survival and determining those patients likely to benefit from adjuvant treatment12,13. Specification (i): Numerator: Number of patients with ER positive, HER2 negative breast cancer who have a e"5% overall survival benefit of chemotherapy treatment predicted at 10 years and/or high risk genomic assay score that undergo adjuvant chemotherapy. Denominator: All patients with ER positive, HER2 negative breast cancer who have a e"5% overall survival benefit of chemotherapy treatment predicted at 10 years and/or high risk genomic assay score. Exclusions: All patients with breast cancer taking part in trials of chemotherapy treatment. All patients with breast cancer who have had neo-adjuvant chemotherapy. All patients with M1 disease.  (continued overleaf) QPI 11: Adjuvant Chemotherapy.continued Specification (ii): Numerator: Number of patients with triple negative or HER2 positive breast cancer who have a e"5% overall survival benefit of chemotherapy treatment predicted at 10 years that undergo adjuvant chemotherapy. Denominator: All patients with triple negative or HER2 positive breast cancer who have a e"5% overall survival benefit of chemotherapy treatment predicted at 10 years. Exclusions: All patients with breast cancer taking part in trials of chemotherapy treatment. All patients with breast cancer who have had neo-adjuvant chemotherapy. All patients with M1 disease. Target:80% The tolerance within this target accounts for factors of patient choice, co-morbidities and fitness for treatment. Please note: Varying evidence exists regarding the most appropriate target level; therefore this may need redefined in the future, to take account of new evidence or when baseline data becomes available.  Revision(s):QPI changed to focus on specific clinical cohorts who are most likely to require adjuvant chemotherapy.  QPI 13: Re-excision Rates QPI Title:Patients undergoing surgery for breast cancer should only undergo one definitive operation where possible. Description: Proportion of surgically treated patients with breast cancer (invasive or in situ) who undergo re-excision or mastectomy following their initial breast surgery. Rationale and Evidence: It is important to minimise treatment related morbidity. Patients undergoing additional surgical procedures can be subject to unnecessary stress, as well as potential complications and delays in recovery14. Re-operation is also a factor related to poorer cosmetic outcomes for patients15. Specifications: Numerator: Number of patients with breast cancer (invasive or in situ) having breast conservation surgery who undergo re-excision or mastectomy following initial breast surgery. Denominator: All patients with breast (invasive or in situ) cancer having breast conservation surgery as their initial or only breast surgery. Exclusions: LCIS aloneTarget:<20% This QPI is measuring the proportion of patients who undergo more than one surgical procedure to achieve clear margins, a less than target level has therefore been set. Please note: Varying evidence exists regarding the most appropriate target level; therefore this may need redefined in the future, to take account of new evidence or when baseline data becomes available.  Revisions:No changes to QPI.  QPI 14: Referral for Genetics Testing QPI Title:Patients with breast cancer should be offered referral to a specialist genetics clinic where appropriate. Description: Proportion of patients with breast cancer who meet the following criteria for gene testing and are referred to a specialist genetics clinic: Please note: This QPI measures 2 distinct elements. Patients with breast cancer who are under 30 years of age; and Patients with triple negative** breast cancer who are under 50 years of age. Rationale and Evidence: Where patients have breast cancer, genetic testing should be offered if their combined BRCA1 and BRCA2 mutation carrier probability is e"10%16. Various prediction models exist to assess the likelihood of a BRCA1 or BRCA2 mutation in a family. All patients with triple negative breast cancer who are under 50 years of age would be predicted to have e"10% probability of a BRCA1 or BRCA2 mutation and should be offered genetic testing17,18. Breast cancer in patients under 30 years of age also increases the likelihood of a BRCA1/BRCA2 or p53 mutation. Some patients may choose not to be seen at Genetics Services following referral. The measurement of this QPI therefore focuses on whether the appropriate patients are being referred to ensure equitable access to the service. It is difficult to accurately capture data for all eligibility criteria for gene testing within current systems, therefore measurement of this QPI will focus on patients under 30 years of age and patients under 50 years of age with triple negative breast cancer. This has been reviewed in line with the recent evidence. specification (i):Numerator: Number of patients with breast cancer under 30 years of age referred to a specialist clinic for genetic testing. Denominator: All patients with breast cancer who are under 30 years of age. Exclusions: No exclusionsSpecification (ii): Numerator: Number of patients with triple negative breast cancer under 50 years of age referred to a specialist clinic for genetic testing.Denominator: All patients with triple negative breast cancer who are under 50 years of age. Exclusions: No exclusionsTarget: 90% The target tolerance level accounts for patients who refuse referral.  Revision(s):Specification (ii) been updated to include patients under 50 years (previously patients under 40 years).  QPI 15: 30 Day Mortality following Chemotherapy QPI Title:30 day mortality following chemotherapy treatment for breast cancer. Description: Proportion of patients with breast cancer who die within 30 days of chemotherapy. Rationale and Evidence: Treatment related mortality is a marker of the quality and safety of the whole service provided by the Multi Disciplinary Team (MDT)10. Outcomes of treatment, including treatment related morbidity and mortality should be regularly assessed. Treatment should only be undertaken in individuals that may benefit from that treatment. This QPI is intended to ensure treatment is given appropriately, and the outcome reported on and reviewed. Specifications: Numerator: Number of patients with breast cancer who undergo chemotherapy that die within 30 days of treatment. Denominator: All patients with breast cancer who undergo chemotherapy. Exclusions: Please note: No exclusions This indicator will be reported separately for neoadjuvant, adjuvant and palliative chemotherapy, as opposed to one single figure. Target:Neoadjuvant and adjuvant treatment <1% Palliative treatment <5%  Revisions:This QPI will remain in all tumour specific QPIs however the measurement will be revised. Data from Chemocare (electronic chemotherapy prescribing system) will be used to maximise the use of data already collected and provide a more accurate picture of all patients with breast cancer undergoing chemotherapy. QPI 16: Clinical Trial and Research Study Access Revision(s): The Clinical Trial & Research Study Access QPI which is applicable to all tumour sites will be included in the final Breast Cancer QPI document.  QPI 17: Genomic Testing QPI Title:Patients with breast cancer should be offered genomic testing where appropriate. Description: Proportion of patients with ER positive, HER2 negative, node negative breast cancer with Nottingham Prognostic Index (NPI) score of >3.4 who undergo genomic testing. Rationale and Evidence: Evidence suggests that gene expression profiling is effective for helping to assist clinicians and patients to make informed decisions on appropriate treatment. These tests can provide an indication of how the disease may progress and therefore assist in treatment planning in relation to chemotherapy19. Tests such as EndoPredict, Oncotype DX Breast Recurrence Score and Prosigna are recommended for guiding adjuvant chemotherapy decisions for people with ER-positive, HER2-negative and lymph node-negative early breast cancer. Validated tools such as PREDICT or The Nottingham Prognostic Index should also be used to determine if a patient is at intermediate risk of distant recurrence20. Specifications: Numerator: Number of patients with ER positive, HER2 negative, node negative breast cancer with NPI score of >3.4 who undergo genomic testing.Denominator: All patients with ER positive, HER2 negative, node negative breast cancer with NPI score of >3.4. Exclusions: Patients with breast cancer taking part in clinical trials of chemotherapy treatment. Patients who undergo neoadjuvant therapy. Target:75% The tolerance within this target accounts for factors of patient choice and fitness for treatment.  Revision(s):NEW QPI  QPI 18: Neo-adjuvant Chemotherapy QPI Title:Patients with breast cancer who receive chemotherapy should be offered neo-adjuvant chemotherapy with the aim of achieving pathological complete response where appropriate. Description: Proportion of patients with triple negative (ER / PR / HER2 negative) or HER2 positive, Stage II or III ductal breast cancer who receive chemotherapy that undergo neo-adjuvant chemotherapy with the aim of achieving pathological complete response. Please note: This QPI measures 2 distinct elements. Patients with triple negative or HER2 positive, Stage II or III ductal breast cancer who receive chemotherapy that undergo neo-adjuvant chemotherapy; and Patients with triple negative or HER2 positive, Stage II or III ductal breast cancer who undergo neo-adjuvant chemotherapy who achieve a pathological complete response. Rationale and Evidence: Pathological complete response is used as an endpoint to predict clinical benefit and survival. Those patients who achieve pathological complete response (defined as ypT0 ypN0) demonstrate improved survival with the greatest benefit shown in aggressive tumour subtypes21. Evidence has shown that pathologic response to neoadjuvant chemo is prognostic in HER2 positive and triple negative breast cancers22. Specification (i): Numerator: Number of patients with triple negative or HER2 positive, Stage II or III ductal breast cancer who receive chemotherapy that undergo neo-adjuvant chemotherapy. Denominator: All patients with triple negative or HER2 positive, Stage II or III ductal breast cancer who receive chemotherapy. Exclusions: NoneTarget:80% The tolerance within this target is designed to accounts for factors of patient choice in relation to treatment decisions for neo-adjuvant chemotherapy as well as patient fitness. Specification (ii): Numerator: Number of patients with triple negative or HER2 positive, Stage II or III ductal breast cancer who undergo neo-adjuvant chemotherapy who achieve a pathological complete response. Denominator: All patients with triple negative or HER2 positive, Stage II or III ductal breast cancer who undergo neo-adjuvant chemotherapy. Exclusions: NoneTarget:30% The tolerance within this target is designed to accounts for the fact that due to tumour variations, not all patients will achieve a pathological complete response. Revision(s):NEW QPI  QPI 19: Deep Inspiratory Breath Hold (DIBH) Radiotherapy QPI Title:Patients with left sided breast cancer or DCIS undergoing adjuvant radiotherapy treatment should use a deep inspiratory breath hold (DIBH) radiotherapy technique. Description: Proportion of patients with left sided breast cancer or DCIS receiving adjuvant radiotherapy treatment to the left breast or chest wall and/or lymphatics who use a DIBH radiotherapy technique. Rationale and Evidence: Left sided breast radiotherapy increases the risk of cardiac morbidity. Excluding the heart from the radiotherapy field minimises the radiation dose to the heart and therefore reduces the risk of longer term cardiac side effects18. Evidence has shown that the use of deep inspiratory breath-hold (DIBH) technique during breast radiotherapy leads to a reduction in the dose of radiation to the heart by 50% without compromising the target coverage. This has been shown to lead to a reduction in future cardiovascular morbidity and mortality18,23. Specifications: Numerator: Number of patients with left sided breast cancer or DCIS receiving adjuvant radiotherapy treatment to the left breast or chest wall and / or lymphatics who use a DIBH radiotherapy technique. Denominator: All patients with left sided breast cancer or DCIS receiving adjuvant radiotherapy treatment to the left breast or chest wall and / or lymphatics. Exclusions: No exclusions. Target:75% The tolerance within this target level accounts for the fact that due to co-morbidities and fitness levels, not all patients will be suitable for DIBH radiotherapy.  Revision(s):NEW QPI  7. Survival Improving survival forms an integral part of the national cancer quality improvement programme. Breast cancer survival analysis will be reported and analysed on a 3 yearly basis by Information Services Division (ISD). The specific issues which will be addressed will be identified by an expert group ahead of any analysis being undertaken, as per the agreed national cancer quality governance and improvement framework. The Breast Cancer QPI Group has identified, during the QPI development process, the following issues for survival analysis: 5 and 10 year overall survival To ensure consistent application of survival analysis, it has been agreed that a single analyst on behalf of all three regional cancer networks undertakes this work. Survival analysis is scheduled as per the national survival analysis and reporting timetable, agreed with the National Cancer Quality Steering Group and Scottish Cancer Taskforce. This reflects the requirement for record linkage and the more technical requirements of survival analyses which makes it difficult for individual Boards to undertake routinely and in a nationally consistent manner. 8. Areas for Future Consideration The Breast Cancer QPI Groups have not been able to identify sufficient evidence, or determine appropriate measurability specifications, to address all areas felt to be of key importance in the treatment of breast cancer, and therefore in improving the quality of care for patients affected by breast cancer. The following areas for future consideration have been raised across the lifetime of the Breast Cancer QPIs: Management of the axilla Secondary breast cancer and recurrence Neoadjuvant Endocrine Therapy Partial Breast Radiotherapy 9. Governance and Scrutiny A national and regional governance framework to assure the quality of cancer services in NHSScotland has been developed; key roles and responsibilities within this are set out below. Appendices 6 and 7 provide an overview of these governance arrangements diagrammatically. The importance of ensuring robust local governance processes are in place are recognised and it is essential that NHS Boards ensure that cancer clinical audit is fully embedded within established processes. 9.1 National Scottish Cancer Taskforce Accountable for overall national cancer quality programme and overseeing the quality of cancer care across NHS Scotland. Healthcare Improvement Scotland Proportionate scrutiny of performance. Support performance improvement. Quality assurance: ensure robust action plans are in place and being progressed via regions/Boards to address any issues identified. Information Services Division (ISD) Publish national comparative report on tumour-specific QPIs and survival for approximately 3 tumour types per annum as part of the rolling programme of reporting. 9.2 Regional Regional Cancer Networks Annual regional comparative analysis and reporting against tumour-specific QPIs. Support national comparative reporting of specified generic QPIs. Identification of regional and local actions required and development of an action plan to address regional issues identified. Performance review and monitoring of progress against agreed actions. Provide assurance to Board Chief Executive Officers that any issues identified have been adequately and timeously progressed. 9.3 Local NHS Boards Collect and submit data for regional comparative analysis and reporting in line with agreed measurability and reporting schedule (generic and tumour-specific QPIs). Utilise local governance structures to review performance, develop local action plans and monitor delivery. Demonstrate continual improvements in quality of care through on-going review, analysis and feedback of clinical audit data at an individual MDT or unit level. 10. References Scottish Government (2016). . Beating Cancer: Ambition and Action Available from:  HYPERLINK "http://www.gov.scot/Resource/0049/00496709.pdf" http://www.gov.scot/Resource/0049/00496709.pdf.Scottish Intercollegiate Guidelines Network (2005). Management of breast cancer in women. Edinburgh: SIGN. Publication No. 84.NHS BSP (2009). Quality Assurance Guidelines for Surgeons in Breast Cancer Screening. Sheffield: NHS Cancer screening Programmes. Publication 20 Fourth Edition.NHS Improvement (2011): Delivering major breast surgery safely as a day case or one night stay (excluding reconstruction) (accessed April 2019).NHS Improvement (2010). Ambulatory breast surgical care: day case/23-hour breast care. NICE (2009). Breast Cancer (Early and Locally Advanced) Diagnosis and Treatment. Cardiff: NICE. CG80.Controversial issues in radiotherapy after breast-conserving surgery for early breast cancer in older patients: a systematic review (accessed April 2019)Tamoxifen with radiotherapy compared with Tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: A systematic review and meta-analysis (accessed April 2019)Kunkler, IH, Williams, LJ, Jack, WJ, Cameron, DA, Dixon, JM, and on behalf of the PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015; 16: 266273NHS Quality Improvement Scotland (2008). Management of breast cancer services. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365 (9472), 16871717.Wishart, G et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010; 12(1): R1.Wishart, G et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012 Aug 21; 107(5): 800807. Jeevan R, Cromwell DA, Trivella M, et al. Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics. BMJ. 2012;345:e4505. doi: 10.1136/bmj.e4505. [ HYPERLINK "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395735/" PMC free article] [ HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/22791786" \t "pmc_ext" PubMed] [ HYPERLINK "http://dx.doi.org/10.1136%2Fbmj.e4505" \t "pmc_ext" Cross Ref].Munshi A, Kakkar S, Bhutani R, Jalali R, Budrukkar A, Dinshaw KA. Factors influencing cosmetic outcome in breast conservation. Clin Oncol 2009;21:285-93. [ HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/19249195" \t "pmc_ext" PubMed].NICE (2013). Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE CG 164. Available from:  HYPERLINK "https://www.nice.org.uk/guidance/cg164" https://www.nice.org.uk/guidance/cg164.Robertson L, Hanson H, Seal S, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012;106(6):1234-8 (accessed April 2019). NICE Guideline 101 July 18 Management of Early and Locally Advanced Breast Cancer (accessed April 2019).NICE Quality Standard 12: Published September 2011 (Updated June 2016) (accessed April 2019).NICE Diagnostics Guidance 34: Published December 2018 (accessed April 2019).Cortazar P, Zhang L, Untch M, et al. Pathological Complete Response and Long Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. Lancet, The, 2014:384(9938): 164-172 (accessed April 2019).Symmans WF, Wei C, Gould R, et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017;35(10):10491060. doi:10.1200/JCO.2015.63.1010 (accessed April 2019).NICE Guideline 101 Evidence Reviews July 2018 (accessed April 2019). 11. Appendices Appendix 1: QPI Development Process Preparatory Work and Scoping NHS Quality Improvement Scotland (formerly Clinical Standards Board for Scotland) Clinical Standards for Breast Cancer have been utilised nationally since 2001. It was therefore agreed that rather than undertake a lengthy QPI development process the extensive literature search and clinical discussion undertaken in the review of NHS Quality Improvement Scotland (NHSQIS) breast standards (in 2008) was used as the basis for QPI development. The preparatory work involved the development group members independently reviewing and assessing the existing NHS QIS Breast Cancer Standards against agreed criteria and identifying any potential gaps where they considered a need to develop new outcome focussed quality indicators. Responses were then collated and the output of this exercise used to inform development group discussions. Indicator Development The Breast Cancer QPI Development Group defined evidence based, measurable indicators with a clear focus on improving the quality and outcome of care provided. The Group developed QPIs using the existing NHS QIS clinical standards as a base. Draft QPIs were then assessed by the Breast Cancer QPI Development Group against three criteria: Overall importance does the indicator address an area of clinical importance that would significantly impact on the quality and outcome of care delivered? Evidence based is the indicator based on high quality clinical evidence? Measurability is the indicator measurable i.e. are there explicit requirements for data measurement and are the required data items accessible and available for collection? Engagement Process A wide clinical and public engagement exercise was undertaken as part of development in 2011 where the Breast Cancer QPIs, along with accompanying draft minimum core dataset and measurability specifications, were made available on the Scottish Government website. During the engagement period clinical and management colleagues from across NHSScotland, patients affected by breast cancer and the wider public were given the opportunity to influence the development of Breast Cancer QPIs. Several different methods of engagement were utilised: Professional groups, health service staff, voluntary organisations and individuals: Wide circulation of the draft documentation for comment and feedback. Patient representative groups: Organised patient focus group sessions were held in conjunction with Cancer Support Scotland (Tak Tent) and Breakthrough Breast Cancer. Following the engagement period all comments and responses received were reviewed by the Breast Cancer QPI Development Group and used to produce and refine the final indicators. Appendix 2: Breast Cancer QPI Development Group Membership (2012) Name DesignationCancer Network/BaseJennifer ArmstrongSenior Medical Officer (CHAIR)Scottish Government Ruth AdamsonConsultant Pathologist (Clinical Lead Subgroup 1)WoSCAN (Crosshouse Hospital, Kilmarnock)Matthew Barber Consultant Surgeon (Clinical Lead Subgroup 2)SCAN (Western General Hospital, Edinburgh)Sophie BarrettConsultant OncologistWoSCAN (Beatson West of Scotland Cancer Centre)Carolyn Bedi Consultant OncologistSCAN (Western General Hospital, Edinburgh)Emma BennettLead Breast Care Nurse SpecialistSCAN (Western General Hospital, Edinburgh)Janet Clarke Consultant RadiographerSCAN (Western General Hospital, Edinburgh)John DewarConsultant Oncologist (Clinical Lead Subgroup 3)NOSCAN (Ninewells Hospital, Dundee)Heather DeansConsultant RadiologistNOSCAN (Aberdeen Royal Infirmary, Aberdeen) Hilary DobsonClinical Director (Clinical Lead Subgroup 1)WoSCAN (WoS Breast Screening Service, Glasgow)Christine DoddsSenior Cancer Audit FacilitatorSCAN (Western General Hospital, Edinburgh)Clare EchlinActing Head of Standards DevelopmentHealthcare Improvement ScotlandSteven HeysConsultant Breast SurgeonNOSCAN (Aberdeen Royal Infirmary, Aberdeen)Alison LanniganConsultant Breast Surgeon (Clinical Lead Subgroup 2)WoSCAN (Wishaw General Hospital, Lanarkshire)Joseph LoaneConsultant PathologistSCAN (Western General Hospital, Edinburgh)Evelyn MacdonaldClinical Nurse SpecialistNOSCAN (Raigmore Hospital, Inverness)Stella MacPhersonPatient Representative Carol MarshallInformation ManagerWoSCANAndy MaylonConsultant Plastic SurgeonWoSCAN (Royal Infirmary, Glasgow)Pauline McIlroyClinical Nurse SpecialistWoSCAN (Beatson West of Scotland Cancer Centre) Brian MurrayNational Cancer Information CoordinatorInformation Services DivisionColin PurdieConsultant PathologistNOSCAN (Ninewells Hospital, Dundee)Iona ScottProject ManagerWoSCAN Name DesignationCancer Network/BaseCarole SmithPatient Representative Evelyn ThomsonRegional Manager (Cancer)WoSCANEva Weiler-MithoffConsultant Plastic SurgeonWoSCAN (Royal Infirmary, Glasgow)Philippa WhitfordConsultant SurgeonWoSCAN (Crosshouse Hospital, Kilmarnock) NOSCAN - North of Scotland Cancer Network SCAN South East Scotland Cancer Network WoSCAN West of Scotland Cancer Network Appendix 3: Breast Cancer QPI Formal Review Group Membership (2016) Name DesignationCancer Network/BaseHilary DobsonChair, National Cancer Quality Steering GroupWoSCANEvelyn ThomsonRegional Manager (Cancer)WoSCANIona ReidClinical Lead Breast Cancer MCNWoSCAN / NHS Greater Glasgow & ClydeGlyn NeadesClinical Lead Breast Cancer MCNSCAN / NHS LothianDouglas BrownClinical Lead Breast Cancer MCNNOSCAN / NHS TaysideWilma JackSenior Clinical Research FellowSCAN / NHS LothianChristine UrquhartCancer Audit ManagerNOSCANIona ScottQuality & Service Improvement ManagerWoSCANJen DohertyNational Cancer Quality Programme Co-ordinatorNational Cancer Quality Programme Formal review of the Breast Cancer QPIs has been undertaken in consultation with various other clinical specialties e.g. Oncology and Genetics Services Appendix 4: 2nd Cycle - Breast Cancer QPI Formal Review Group Membership (2018) Name DesignationCancer Network/BaseSeamus Teahan (Chair)Consultant Urological Surgeon and Regional Lead Cancer ClinicianWoSCANDougal AdamsonConsultant Clinical OncologistNCAAbdulla AlhassoConsultant Clinical OncologistWoSCANSharon ArmstrongConsultant Medical OncologistNCAMatthew BarberClinical Lead Breast Cancer MCNSCANDouglas BrownClinical Lead Breast Cancer MCNNCAChristine DoddsSenior Audit FacilitatorSCANJen DohertyNational Cancer Quality Programme Co-ordinatorNational Cancer Quality ProgrammeLisa FowlerCancer Support ManagerNCAGraeme LumsdenConsultant Clinical OncologistWoSCANKate MacDonaldRegional Manager (Cancer)SCANHusam MarashiConsultant Clinical OncologistWoSCANTrevor McGoldrickConsultant Medical OncologistNCAJames MansellClinical Lead Breast Cancer MCNWoSCANLorraine StirlingProject OfficerNational Cancer Quality ProgrammeChristine UrquhartCancer Audit ManagerNCAFrances YuilleConsultant Clinical OncologistSCAN Formal review of the Breast Cancer QPIs has been undertaken in consultation with various other clinical specialties e.g. Oncology, Radiotherapy and Genetics Services Appendix 5: 3-Yearly National Governance Process and Improvement Framework for Cancer Care This process is underpinned by the annual regional reporting and governance framework (see appendix 6).   1. National QPI Development Stage QPIs developed by QPI development groups, which include representation from Regional Cancer Networks, Healthcare Improvement Scotland, ISD, patient representatives and the Cancer Coalition.   2. Data Analysis Stage: NHS Boards and Regional Cancer Advisory Groups (RCAGs)* collect data and analyse on yearly basis using nationally agreed measurability criteria and produce action plans to address areas of variance. Submit yearly reports to ISD for collation and publication every 3 years. ISD produce comparative, publicly available, national report consisting of trend analysis of 3 years data and survival analysis. National comparative report approved by NHS Boards and RCAGs.    3. Expert Review Group Stage (for 3 tumour types per year): Expert group, hosted by Healthcare Improvement Scotland, review comparative national results. Write to RCAGs highlighting areas of good practice and variances. Where required NHS Boards requested to submit improvement plans for any outstanding unresolved issues with timescales for improvement to expert group. Improvement plans ratified by expert group and Scottish Cancer Taskforce.   4. Improvement Support Stage: Where required Healthcare Improvement Scotland provide expertise on improvement methodologies and support.   5. Monitoring Stage: RCAGs work with Boards to progress outstanding actions, monitor improvement plans and submit progress report to Healthcare Improvement Scotland. Healthcare Improvement Scotland report to Scottish Cancer Taskforce as to whether progress is acceptable.  6. Escalation Stage: If progress not acceptable, Healthcare Improvement Scotland will visit the service concerned and work with the RCAG and Board to address issues. Report submitted to Scottish Cancer Taskforce and escalation with a proposal to take forward to Scottish Government Health Department.*In the South and East of Scotland Cancer Network (SCAN) the Regional Cancer Planning Group is the equivalent group to Regional Cancer Advisory Group (RCAG). Appendix 6: Regional Annual Governance Process and Improvement Framework for Cancer Care   1. Regional QPI Implementation Stage: National cancer QPIs and associated national minimum core dataset and measurability specifications, developed by QPI development groups. Regional implementation of nationally agreed dataset to enable reporting of QPIs.     2. Data Analysis Stage: NHS Boards collect data and data is analysed on a yearly basis using nationally agreed measurability criteria at local/ regional level. Data/results validated by Boards and annual regional comparative report produced by Regional Networks. Areas of best practice and variance across the region highlighted. Yearly regional reports submitted to ISD for collation and presentation in national report every 3 years.   3. Regional Performance Review Stage: RCAGs* review regional comparative report. Regional or local NHS Board action plans to address areas of variance developed. Appropriate leads identified to progress each action. Action plans ratified by RCAGs. 4. Monitoring Stage: Where required, NHS Boards monitor progress with action plans and submit progress reports to RCAGs. RCAGs review and monitor regional improvement.     5. Improvement Support Stage: Where required Healthcare Improvement Scotland maybe requested to provide expertise to NHS Boards/RCAGs on improvement methodologies and support.   6. Escalation Stage: If progress not acceptable, RCAGs will escalate any issues to relevant Board Chief Executives. If progress remains unacceptable RCAGs will escalate any relevant issues to Healthcare Improvement Scotland. *In the South and East of Scotland Cancer Network (SCAN) the Regional Cancer Planning Group is the equivalent group to Regional Cancer Advisory Group (RCAG). Appendix 7: Glossary of Terms Adjuvant therapy / treatmentTreatment given in addition to the primary therapy, or a secondary remedy assisting the action of another.Age-standardised Age-standardisation facilitates comparisons across geographical areas by controlling for differences in the age structure of local populations.AxillaThe armpit.Axillary clearanceOperation to remove all the lymph glands from under the arm.BiopsyRemoval of a sample of tissue from the body to assist in diagnosis of a disease. BreastGlandular organ located on the chest. The breast is made up of connective tissue, fat, and breast tissue that contains the glands that can make milk. Also called mammary gland.Cause-specific survival A method of estimating net survival. Only deaths attributable to the cancer of diagnosis are counted as deaths, giving the probability of survival in the absence of other causes of death. ChemotherapyThe use of drugs that kill cancer cells, or prevent or slow their growth.Co-morbidityThe condition of having two or more diseases at the same time.Conservation surgeryAn operation to remove the breast cancer but not the breast itself. Types of breast-conserving surgery include lumpectomy (removal of the lump), quadrantectomy (removal of one quarter, or quadrant, of the breast), and segmental mastectomy (removal of the cancer as well as some of the breast tissue around the tumour and the lining over the chest muscles below the tumour).Core biopsyRemoval (using a needle) of a piece of a breast tissue for diagnosis.Day caseDay surgery is the admission of selected patients to hospital for a planned surgical procedure, returning home on the same day.Deep Inspiratory Breath Hold (DIBH) RadiotherapyA radiation therapytechnique where patients take adeep breathduring treatment, andholdthisbreath for up to 30 secondswhile the radiation is delivered. This action inflates the lungs and pushes your heart away from the chest wall and away from the area being treated.Definitive procedure/ treatmentThe treatment plan for a disease or disorder that has been chosen as the best one for a patient after all other choices have been considered.Deprivation Currently, the Scottish Index of Multiple Deprivation (SIMD) is used to estimate an individuals level of affluence. This is based on seven domains (income, employment, education, housing, health, crime, and geographical access) combined into an overall index. Ductal Carcinoma In Situ (DCIS)When the breast cancer cells are completely contained within the ducts (the channels in the breast that carry milk to the nipple) and have not spread into the surrounding breast tissue.Excision MarginsThe edge or border of the tissue removed in surgery. Fine Needle Aspiration (FNA)The withdrawal of fluid, containing cells, from the body by means of suction using a fine needle. The samples obtained are used to provide information on the cells of tumours or cysts.Fluorescence In Situ Hybridization (FISH)This is a lab test that measures the amount of a certain gene in cells. It can be used to see if an invasive cancer has too many HER2 genes.GeneticInherited; having to do with information that is passed from parents to offspring through genes in sperm and egg cells.Genomic TestingA type of medical test that identifies changes in chromosomes, genes, or proteins. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a persons chance of developing or passing on a genetic disorder.Histological / HistopathogicalThe study of the structure, composition and function of tissues under the microscope, and their abnormalities.Hormonal therapyTreating a disease with hormones, or by blocking the action of hormones.Human Epidermal growth factor Receptor (HER) 2One of many receptors on the surface of certain cells which can protect the cell from damage or stimulate it to grow. This is the target, present on some breast cancer cells, which is hit by Herceptin (trastuzumab).Immediate Breast ReconstructionBreast reconstruction carried out at the same time as the operation to remove the breast.Immunohistochemistry (IHC)A technique used to identify specific molecules in different kinds of tissue. The tissue is treated with antibodies that bind the specific molecule. These are made visible under a microscope by using a colour reaction, a radioisotope, colloidal gold, or a fluorescent dye. Immunohistochemistry is used to help diagnose diseases, such as cancer, and to detect the presence of micro organisms. It is also used in basic research to understand how cells grow and differentiate (become more specialized).In situ A cancer that is in place, is non-invasive, has not spread beyond the initial location.InvasiveCancer that can or has spread from its histological original site.LesionTumour, mass, or other abnormality.Lobular Carcinoma In Situ (LCIS)A condition in which abnormal cells are found in the lobules of the breast. Lobular carcinoma in situ seldom becomes invasive cancer; however, having it in one breast increases the risk of developing breast cancer in either breast.Lymph NodesSmall bean shaped organs located along the lymphatic system. Nodes filter bacteria or cancer cells that might travel through the lymphatic system.Malignant/MalignancyCancerous. Malignant cells can invade and destroy nearby tissue and spread to other parts of the body.MastectomySurgical removal of a breast.Metastases/Metastatic Spread of cancer away from the primary site to somewhere else via the bloodstream or the lymphatic system. MorbidityHow much ill health a particular condition causes. Morphology / MorphologicallyThe science of the form and structure of organisms (plants, animals, and other forms of life).Multidisciplinary team meetingA meeting which is held on a regular basis, which is made up of participants from various disciplines appropriate to the disease area, where diagnosis, management, and appropriate treatment of patients is discussed and decided.Multifocal diseaseOccurring in more than one location in the breast. Neoadjuvant therapy / treatmentDrug treatment which is given before the treatment of a primary tumour with the aim of improving the results of surgery or chemotherapy and preventing the development of metastases.Observed survival A method of estimating the actual survival prospects of patients following diagnosis. Includes deaths from all causes and does not adjust for underlying differences in patient populations.PathologicalThe study of disease processes with the aim of understanding their nature and causes. This is achieved by observing samples of fluid and tissues obtained from the living patient by various methods, or at post mortem.Prognostic indicators Factors, such as staging, tumour type or deprivation that may influence treatment effectiveness and outcomes.PsychologicalHaving to do with how the mind works and how thoughts and feelings affect behaviour.RadiotherapyThe use of radiation, usually X-rays or gamma rays, to kill tumour cells.Randomised Clinical TrialsA study to test a specific drug or other treatment in which people are randomly assigned to two (or more) groups: one (the experimental group) receiving the treatment that is being tested, and the other (the comparison or control group) receiving an alternative treatment, a placebo (dummy treatment) or no treatment. The two groups are followed up to compare differences in outcomes to see how effective the experimental treatment was. (Through randomisation, the groups should be similar in all aspects apart from the treatment they receive during the study.) RecurrenceWhen new cancer cells are detected at the site of the original tumour, following treatment.Relative survival A method of estimating net survival. The ratio of observed survival divided by expected survival, where the expected survival is based on the life expectancy of the population (from lifetables). This can be thought of as a measure of the survival expectation after developing cancer, or the probability of survival from cancer in the absence of other causes of death.Sentinel node biopsyThe lymph node near a body organ or part of an organ which is thought to be the first reached by tissue fluid draining from that organ, this lymph node may be the one most likely to contain cancer cells if the cancer has begun to spread.StagingProcess of describing to what degree cancer has spread from its original site to another part of the body. Staging involves clinical, surgical and pathology assessments. Surgery/Surgically Surgical removal of the tumour/lesion.Surgical marginsSee Excision MarginsSurvivalThe percentage of people in a!"HIQW_`Ҽҕyn`ZTF;hP65CJ^JaJhP6hP65CJ^JaJ hH^J hq|^JhChGIX5CJ,^JaJ,h1 5CJ,^JaJ,h1 hn5CJ4^JaJ4h1 hGIX5CJ4^JaJ4h1 h}5CJ4^JaJ4hJh ;5CJ,^JaJ,hn5CJ,^JaJ,hGIX5CJ,^JaJ,hH5CJ,^JaJ,hJhGIX5CJ,^JaJ,$jhJhGIXU^JmHnHuh3uh~5CJaJ"IJKLMNOPQ`]gdP6 x]gd1 ]gd*B$a$gdGIX$a$gd~> . Q / N {] " $]a$gd ]gd ]gdP6  8 9 : ; ±zdYJY8JY#jyhPUmHnHujhPUmHnHuhPmHnHu*jhAWhP0JUmHnHuhPmHnHuhAWhP0JmHnHu$jhAWhP0JUmHnHuh 9HhGIXOJQJ^J!jh 9HhGIXOJQJU^JhJhGIX5CJ^JaJh h 5CJ^JaJh 5CJ,^JaJ,h1 5CJ,^JaJ,h1 5CJ^JaJ; < = > ? @ Z [ \ ]  ƹse\eFe*jhAWhP0JUmHnHuhPmHnHuhAWhP0JmHnHuhP5OJQJ\^JjkhPUjhPU hPjhAWhP0JUhPhAWhP0JjhAWhP0JU-hP56CJOJQJ\]aJmHnHu$jhAWhP0JUmHnHujhPUmHnHu   ( ) * + , - . / 0 J K L M i j k }kU*jhAWhP0JUmHnHu#jOhPUmHnHu*jhAWhP0JUmHnHuhPmHnHuhAWhP0JmHnHu-hP56CJOJQJ\]aJmHnHu$jhAWhP0JUmHnHu#j]hPUmHnHujhPUmHnHuhPmHnHu!     1 2 3 K L M N O P Q R S m n o p |jT*jhAWhP0JUmHnHu#j3hPUmHnHu*jhAWhP0JUmHnHuhPmHnHuhAWhP0JmHnHu-hP56CJOJQJ\]aJmHnHu$jhAWhP0JUmHnHu#jAhPUmHnHuhPmHnHujhPUmHnHu    ( ) * , - . / 0 1 K L zpzcpzpVhP5OJQJ\^JjhPUjhPU hPjhAWhP0JUhPhAWhP0JjhAWhP0JU-hP56CJOJQJ\]aJmHnHu$jhAWhP0JUmHnHu#j%hPUmHnHuhPmHnHujhPUmHnHuL M N l m n     - . / G H I K L M N Խ٬ٜԏ٬rj hPUjt hAWhP0JUjhPUjhAWhP0JUhPhP5OJQJ\^Jj hPUjhPU hPhAWhP0JjhAWhP0JUjhAWhP0JU,N O P j k l m    %&'(Z[\tuvйЏrj hPUjJ hAWhP0JUj hPUjX hAWhP0JUhP5OJQJ\^Jj hPUjhPU hPjf hAWhP0JUhPhAWhP0JjhAWhP0JU,vxyz{|}<=>VWXZ[\]^_yz{|͹͜j hAWhP0JUjhPUj.hAWhP0JUj hPUj< hAWhP0JUhPhAWhP0JhP5OJQJ\^JjhAWhP0JUjhPU hP.  /012WXYqrsuvwxyzsjhAWhP0JUj}hPUjhAWhP0JUjhPUjhAWhP0JUhPhAWhP0JhP5OJQJ\^JjhAWhP0JU hPjhPUjhPU-]xW4C6-_gd%m^$a$gd%m^gd> "678PQRTUVWXYstuvjShPUjhAWhP0JUjahPUjhAWhP0JUhPhAWhP0JhP5OJQJ\^JjhAWhP0JUjohPUjhPU hP-    +,-.fghԽ٬ٜԏ|nenhPmHnHuhAWhP0JmHnHu$jhAWhP0JUmHnHuj7hPUjhAWhP0JUhPhP5OJQJ\^JjEhPUjhPU hPhAWhP0JjhAWhP0JUjhAWhP0JU -./123456PQɾ׆}gɾU׆}#jhPUmHnHu*jhAWhP0JUmHnHuhPmHnHu-hP56CJOJQJ\]aJmHnHu#j)hPUmHnHujhPUmHnHuhPmHnHuhAWhP0JmHnHu$jhAWhP0JUmHnHu*jhAWhP0JUmHnHu QRSmnoɾ׆yplp\ypVpQGQjhPU hP hX0JjhAWhP0JUhPhAWhP0JjhAWhP0JU-hP56CJOJQJ\]aJmHnHu#j hPUmHnHujhPUmHnHuhPmHnHuhAWhP0JmHnHu$jhAWhP0JUmHnHu*jhAWhP0JUmHnHu"#$<=>@ABCDE_`abegyz{}jhPUjjhAWhP0JUjhPU hX0JjxhAWhP0JUhPhAWhP0JhP5OJQJ\^JjhAWhP0JU hPjhPUjhPU*/013456ߵ}gߵU}#jhPUmHnHu*jNhAWhP0JUmHnHu-hP56CJOJQJ\]aJmHnHu#jhPUmHnHujhPUmHnHuhPmHnHu*j\hAWhP0JUmHnHuhPmHnHuhAWhP0JmHnHu$jhAWhP0JUmHnHu 678RSTUxyz6789|}~йЏrj hPUj$ hAWhP0JUjhPUj2hAWhP0JUhP5OJQJ\^JjhPUjhPU hPj@hAWhP0JUhPhAWhP0JjhAWhP0JU,   &'(*+,-./IJKL͹͉ͬͦ|j"hPUj"hAWhP0JUj!hPU hX0JhAWhP0JOJQJj!hAWhP0JUhPhAWhP0JhP5OJQJ\^JjhAWhP0JUjhPU hP+>?@XYZ\]^_`a{|}~Խ٬ٜԏⰄuh^helCJ^JaJhZhGIXCJ^JaJh>hGIXCJaJhGIXjh 9HhGIXUje$hPUj#hAWhP0JUhPhP5OJQJ\^Jjs#hPUjhPU hPhAWhP0JjhAWhP0JUj"hAWhP0JU! $Y23KMɼxm``````hhj*CJ^JaJhY-hj*CJaJh?CJaJh'!hj*CJaJhj*CJaJhhj*CJaJhyCJ^JaJh?CJ^JaJhj*CJ^JaJh fh}CJ^JaJh}CJ^JaJh fCJ^JaJh6CJH*^JaJh6h6CJH*^JaJh6CJ^JaJ%!!/#0#k#l#$$%%&&&&@(gdj*gd{Agd/#gd!5gd@Fgd@Fgd?gdj*gdr035 = D W -!.!/!2!!!F"Q"R"Z"["h""".#0#P#V#k#l##$$<%h%%%Ǽ隍shr 6h fCJ^JaJhr 6hMICJ^JaJhr 6h(CJ^JaJhJhj*CJ^JaJhZhj*CJ^JaJhCJaJh/#hj*CJaJh!5CJ^JaJh fCJ^JaJhhj*5CJ^JaJhj*CJ^JaJhhj*CJ^JaJ*%%%%%%%&h&q&&&&&&&&&&&'/'B'X'Y'_'`'f'g'(%(?(@(A(`(((((((ǼDZ}pppfh~CJ^JaJhBS hr 6CJ^JaJhr 6CJ^JaJhr 6h fCJ^JaJhCJ^JaJhr 6hj*CJaJhj*CJaJhWNhj*CJaJhugshj*CJaJhj*CJaJhj*CJ^JaJh3h(CJ^JaJh3hj*CJ^JaJhr 6hj*CJ^JaJ(@(A(**++--c-d-.L....-/.///`0 & Fgd{Agd{AgdZ<gdZgdY- & FgdA> & Fmx`mgdA> & Fmxx`mgdA>gdr 6gdj*(((G)L)^){))))))****D*Y*****#++++b,w,,,,,,, --d-w-Կ鑇}}s}ssehJhj*5CJ^JaJhsUCJ^JaJhVNjCJ^JaJhgCJ^JaJhj*CJ^JaJhr 6CJ^JaJh hr 6CJ^JaJhBS hBS CJ^JaJ)hBS hBS CJ^JaJfHq )hBS hr 6CJ^JaJfHq h~CJ^JaJhBS hr 6CJ^JaJ%w-..L.Y....-/.////0'00011m1111111122222^4ƻ||tiaiYhj*CJaJh3CJaJhch(CJaJhCJaJhGIXCJ\^JaJh+CJ\^JaJhJhGIX5CJ\^JaJhJhGIXCJ\^JaJhhGIXCJaJhZhCJaJhyVhj*0JCJaJh!5CJaJhj*CJ^JaJhJhj*5CJ^JaJhJhj*CJ^JaJ `0a000112222]4^45554555^6_6`6a6b6c6gd$I$a$gdSgdN_`gdN_gd0hgd8mgdj*gd{A & Fgd{Ae^egd{A^45 55545555555556J6Y6Z6[6^6_6b6f6j6k6l6666ͽͤ͛͏ztplh]RGRh0rhDCJaJh0rhSCJaJh0rh$ICJaJh3h@Fh$I h$ICJh$ICJ\aJhih3CJ\aJhihN_CJ\aJhgCJ\aJh$6hN_CJ\aJhN_CJ\aJmH sH h$6hN_CJ\aJmH sH hN_CJ\aJhN_h0hhN_CJaJh8mCJaJhj*CJaJhohj*CJaJc6d6e6f6g6h6i6j66666677$ t"$If]a$gd7^f $Ifgd7^fgd7^fgd"Tgd0rgd0rgd$I6666666666677<7>7G7S7_77777777778ƿxrkdZdSL hi56 h8nhih8nhi6CJ hi6CJ h8nh8n hCJ h%vh7^fhmhtG0J26]h7^f0J26CJ]aJhi0J26CJ]aJh7^fh7^f0J26CJ]aJh%vh7^f56 h7^f56 h7^fh7^fh"Th*B6CJaJh"Th8n6CJaJh"Th6CJaJ h0rh0rhSCJaJ7777778`XSNI@ $Ifgdigdigdigd8n$a$gd+kd$$$Ifl0 p# x @@ t0p#644 l` alpyt7^f88#898>8g8p8{888888888889:6:7:8:9:::?:R:S:T:ƾ{g`XOH h'Oh'Oh'O6CJaJh0r0JCJ hShi'hih"T0J26B*CJ]aJphh./0J26CJ]aJhShi56 h8nh8nh+6CJaJh8nh+6CJaJh8n6CJaJ h./h./hi0JCJ h%vhihmhi0J26]hi0J26CJ]aJh7^fhi0J26CJ]aJh%vhi5688888883.gd./gdikd%$$Ifl0 p# x @@ t0p#644 l` alpyti$ t"$If]a$gd0r$ t"$If]a$gdi8889y997:8: t"dd$If[$\$]gd5+ t"dd$If[$\$]gdidd$If[$\$gdigd{Agd{A8:9:::S:T:_:#;`[[VM9$ t"$If]a$gdtG $IfgdtGgd{Agd{Akd|&$$Ifl0 "  @@ t0"644 l` alpytiT:^:_:::::::::#;;;;;;;;;;;;;;;;<<<'<+<<<<<<<ҹ{Źtehhh6CJaJ hch+hj~0J26CJ]aJ h'Oh'O h+6CJh'Oh+6CJ h'O6CJh0r h0r6CJ h%vhtGhmhtG0J26]htG0J26CJ]aJh./0J26CJ]aJh7^fhtG0J26CJ]aJh%vhtG56 htG56%#;$;;;;;;;LC>Cgd0rgd0rkdK'$$Ifl0 p# x @@ t0p#644 l` alpyttG$ t"$If]a$gdtG;;;;<<<5kd($$Ifl0 p# x @@ t0p#644 l` alpyttG$ t"$If]a$gdtG $IfgdtGgd{Agd0r<<<<<<==,=9=======??/?1?I?^?d???????@@@@?BBB CCCCC CCCCCCCCCDDDỮ̓̓ņjhch=0JUhch=6 h=5hJhJH* hJh=hMh=5jh=0JUh= hch=hch=5 h'Oh'Ohh+6CJaJhh6CJaJhh'O6CJaJ4<<<<*=+=,=9=:===_kd($$Ifl0 # 3  t 0+$644 lap ytfi $Ifgdfigd{Agd =!>">>???/?0?1?Tkd)$$Ifl0 # 3  t 0+$644 lap ytfi & F$If^`gd.wg $Ifgdfi 1?@@@BABBBBCCCC Cikd7*$$Ifl0 # 3  t 0+$644 lap ytfi $Ifgdfi CCCCCCCCQkd*$$Ifl4F j#` U  t 0+$6    44 laf4p ytfi $IfgdfiCCCCCDD\SSSFF & F$IfgdA> $Ifgdfikd+$$Ifl4F j#  U  t 0+$6    44 laf4p ytfiDDD"D&DUDDDEEEEMEOE\EaEcEeEpErEEFFFFF>FfFuFFFFFFFFFFFG%G1GGGGGGGGGGGHHhSh=0J26CJ]aJh=0J26CJ]aJ h=56hSh=56h=5CJaJh.wgjhch=0JUhch=6 h=5hJh=5CJaJh0rhch=5 hch=h=5DDD"D&D'DEEMDDDDD $Ifgdfikd,$$Ifl4fF j#  U  t 0+$6    44 laf4p ytfi h$If^hgdfiEEEEMENEOEcEdEeEriid__VVV $Ifgdfigd=gdJP^Pgd=kd-$$Ifl0 # 3  t 0+$644 lap ytfi eEqErEFFFFFsFtFQkdu.$$Ifl4F j#` U  t 0+$6    44 laf4p ytfi $Ifgdfi tFuFvFFFFFF\SSSFFF & F$IfgdA> $Ifgdfikdc/$$Ifl4F j#  U  t 0+$6    44 laf4p ytfiFFFFFFGGMDDDDD $Ifgdfikd[0$$Ifl4fF j#  U  t 0+$6    44 laf4p ytfi h$If^hgdfiGGGGG,HHHrmm]EEE t"dd$If[$\$]gdfidd$If[$\$gdfigd=kdW1$$Ifl0 # 3  t 0+$644 lap ytfiHHHHHHHHH`[VQLLLLgd-gd-gd=gd=kd 2$$Ifl0 #  @@ t0#644 l` alpyt0rHHHHHHHHHHHHHHHI7IWIdIIIIJJ KKpKKKKKKKK L-LLLLMMMMMMMz hVt 5 hVt ^JhABM hJH*hQhVt 5hVt hchVt hchVt 5 h'Oh'O hhE6CJh'Oh(u6CJ h6CJ h(u6CJ hj~6CJhLuh-h-6CJaJh=6CJaJh=5CJaJ hSh=-HHHHHUIVIWIdIeIIZkd2$$Ifl0 # 3  t 0+$644 lap ytfi $Ifgdfigd*Bgd(ugd- IIIIdJJJJ?kd3$$Ifl0 # 3  t 0+$644 lap ytfi & FW$If^`Wgd.wg & F$If^`gd.wg $IfgdfiJ K KKKKLLMMMMMikd)4$$Ifl0 # 3  t 0+$644 lap ytfi $Ifgdfi MMMMTNUNVNWNeNNQkd4$$Ifl4F j#` U  t 0+$6    44 laf4p ytfi $Ifgdfi MM0N2N?NSNVNeNNNNNNNGOTOYO[O]OhOiOjOOOPPPP>PbPePrPsPtPPPPPPPPPPPPPP>QGQuRvRxRzRR|SSSSTT¶쪟hVt CJaJh]hVt CJaJh]hVt 5CJaJhJhzR5CJaJhzR5CJaJhJhVt 5CJaJhzRhJ hVt 5hchVt 5hVt hchVt hchVt 6;NNNNNNEOSF & F$IfgdA>kd5$$Ifl4F j#  U  t 0+$6    44 laf4p ytfi $IfgdfiEOFOGO[O\O]OiOjOMDDDDD $Ifgdfikd6$$Ifl4F j#  U  t 0+$6    44 laf4p yt.wg h$If^hgdfijOPPPPPcPdPDkd7$$Ifl4F j#` U  t 0+$6    44 laf4p yt.wg h$If^hgdfi $IfgdfidPePfPsPtPPPZQQQD7 h$If^hgdfi & F$IfgdA> $Ifgdfikd8$$Ifl4F j#  U  t 0+$6    44 laf4p yt.wgPPPPPPPPPZULUUUUUP^PgdVt gdVt kd9$$Ifl4F j#  U  t 0+$6    44 laf4p yt.wgPPPPPPPPvRwRxR[kd:$$Ifl0 # 3  t 0+$644 lap ytfi $Ifgdfir]rgdzRgdVt xRyRzRRTTTTTTT t"$If]gd.wgdd$If[$\$gdfi^gdVt gdVt TT TTTTTTTTTTTTTTTUDUEUOU\U]UUUUUUUVV0VVVXXXXXXXXzvzzovovovozzjzvzvzz hJH* hhh hchhch5 h'Oh'O h+6CJh'Oh+6CJ h6CJ h'O6CJhch+CJhVt CJaJ hShVt hSh.wg0J26CJ]aJhVt 0J26CJ]aJ hVt 56hShVt 56hJQhVt CJaJ)TTTTTTUMUNU`[[VQHHH $Ifgdgd*Bgd*BgdVt kd[;$$Ifl0 "  @@ t0"644 l` alpytfiNUOU\U]UVVriiii $Ifgdkd*<$$Ifl0 # 3  t 0+$644 lap ytVV0V1V2VVVrWsWXXriiiiiiiii $Ifgdkd<$$Ifl0 # 3  t 0+$644 lap yt XXXXXXXYYriiiiiii $Ifgdkdx=$$Ifl0 # 3  t 0+$644 lap ytXXX&Y'Y6YPYQYgYYYYYYYYYYaZbZcZkZ[[U[V[[[[[[\\\\\\\\\|rkd h+6CJ hP6CJh'Oh+6CJ h6CJ h'O6CJhch+CJ hShhSh0J26CJ]aJh0J26CJ]aJhSh56 hCJ h hh h5 hch.wghch5 hhh hchhch6'YYYYYYZQQQQ $Ifgdkd>$$Ifl4F j#` U  t 0+$6    44 laf4p ytYYYYY ZaZ\SSSFF & F$IfgdA> $Ifgdkd ?$$Ifl4F j#  U  t 0+$6    44 laf4p ytaZbZcZkZoZpZ[[MDDDDD $Ifgdkd@$$Ifl4F j#  U  t 0+$6    44 laf4p yt h$If^hgd.wg[[[[[[[id_Odd$If[$\$gdAgdgdkdA$$Ifl0 # 3  t 0+$644 lap yt $Ifgd[[\\\\\LGBgd*Bgd*BkdA$$Ifl0 # x @@ t0#644 l` alpytA t"dd$If[$\$gd\\\ ]^^^^ _:_<_`!`I`M`e`g`zaabbbbccccccddJeRepeeeJfNf[f\f]ffffffff g9g:gggggggggh潳hZ0J26CJ]aJ hZ56hShZ56 h:hZhchZ6h ~hZH*hJhJH*h)DP hZ^J hchZhZhchZ5 h'Oh'O;\\^^^ _ _K`L``kdB$$Ifl0 # 3  t 0+$644 lap ytfi $Ifgdfi $IfgdfiL`M`e`f`g`aabbccriiiiiiiii $Ifgdfikd,C$$Ifl0 # 3  t 0+$644 lap ytfi cccccccNePeriiiiiii $IfgdfikdC$$Ifl0 # 3  t 0+$644 lap ytfiPeReTepeLfMfZQQQQ $IfgdfikdzD$$Ifl4F j#` U  t 0+$6    44 laf4p ytfiMfNfOf\f]fff\SSSF9 h$If^hgd a & F$IfgdA> $IfgdfikdhE$$Ifl4F j#  U  t 0+$6    44 laf4p ytfifffffggZQQQQQ $Ifgdfikd`F$$Ifl4F j#  U  t 0+$6    44 laf4p ytfigggggZh[hrmm]II t"dd$If[$\$gdfidd$If[$\$gdfigdZkd\G$$Ifl0 # 3  t 0+$644 lap ytfih4h5hZh[h\h^h_hdheh|h}h~hhhi ii5ijjjjjjjjVkZk\kȿ{w{ohd^dTdhdLdhohWh<5jh<0JU h<^Jh< hch<hch<5hG hchGhchG5 h'Oh'O h+6CJhIX[h+0J6CJaJh0J6CJaJhIX[h'O0J6CJaJhch+CJ hZCJ hShZhShZ0J26CJ]aJhZ0J26CJ]aJhZh]phZ56[h\h]h^h}h~hh i i`[[VQHHH $Ifgdfigd*BgdgdZkdH$$Ifl0r #  @@ t0$644 l` apytzR i iiijjVkXkriiii[[ $7$8$H$Ifgd< $IfgdfikdH$$Ifl0 #D 3  t 0w#644 lap ytfiXkZk\k^kfklpggg^ $Ifgd0r $IfgdfikdI$$Ifl40 #`D 3  t 0w#644 lap yt<\k^kdkfkkkkkkkkkPldlnlpllllllllllllllmmnnn n%n(n)nAnnnnnnnIoJoLoMoppppppppppĽěĽēhchG6 hG5 hJH*\ hG\hchG\hG hJH* hchGhchG5hch<5jh<0JU^J hCw^Jh /h<^J h<^Jh< hch<:lllll'n(nJAAAAA $IfgdfikdDJ$$Ifl4\ # D G3  t 0w#644 lap yt<(n)nAnBnCnnnNoJAAAAAA $IfgdfikdUK$$Ifl4\ # D G3  t 0w#644 lap yt<NoOopppppppp.s0sikdXL$$Ifl0 #D 3  t 0w#644 lap ytfi $Ifgdfi pprrr2sPstsxssssssatdtqtrtst u u,u0u1uGurusutuuuuuuuuvvvvw*wwwx x-x.x/xxxxxxxgyiyvyyy5z7z9zƶ h hGh hG5 hG5hJhG0J56CJaJhJhG5CJaJhyhchG6h /hG^JhchG5 hG^JhG hchG=0s2s4sPsbtctZQQQQ $IfgdfikdL$$Ifl4F  #`D U  t 0w#6    44 laf4p ytfictdtetrtstt u*u\SSSFFF & F$IfgdA> $IfgdfikdM$$Ifl4F  # D U  t 0w#6    44 laf4p yt<*u+u,u-u.u/u0uMHHH; ^`gdGgdGkdN$$Ifl4_F  # D U  t 0w#6    44 laf4p yt< h$If^hgdfi0u1uFuGusutuuuuuuvv $IfgdfigdJgdG ^`gdG vvvwxxZQQQQ $IfgdfikdO$$Ifl4F  #`D U  t 0w#6    44 laf4p ytfix x!x.x/xxxx\SSSFFF & F$IfgdA> $IfgdfikdP$$Ifl4F  # D U  t 0w#6    44 laf4p ytfixxxxxxhyiyMDDDDD $IfgdfikdQ$$Ifl4_F  # D U  t 0w#6    44 laf4p ytfi h$If^hgdfiiy7z8z9z:zGzzzidT@@ t"dd$If[$\$gdfidd$If[$\$gdfigdGkdR$$Ifl0 #D 3  t 0w#644 lap ytfi $Ifgdfi9z:zBzCzDzEzGzzzzzzzzzzzz{G{J{K{X{Y{{{{{{{||||rchJCJH*OJQJ^JaJ hDgWhACJOJQJ^JaJ h hA hchA h}hAhAhchA5 h'Oh\h'Oh\6CJ h\6CJhch+CJ hShGhShG0J26CJ]aJhG0J26CJ]aJ hG56hShG56 hGCJ!zzzzzzI{J{`[VQHHH $IfgdJgd\gd\gdGkdxS$$Ifl0r "  @@ t0q#644 l` apytJJ{K{X{Y{{{tkkkk $IfgdJkdGT$$Ifl0 # 3  t 0+$644 lap ytJ{{|||;}<}tkkk[[!$If[$\$gdJ $IfgdJkdT$$Ifl0 # 3  t 0+$644 lap ytJ|||5}7}:};}<}=}M}O}Z}\}}}}~~~~~l~m~~~~~~~~~~~~~ ;kmz9;<=>򹲪yys hACJh hA5 h}hA h hAhA h}KhAh}KhA6h}KhA5hchA5 hchAh(FhAB*phhJCJH*OJQJ^JaJ hDgWhACJOJQJ^JaJhABMCJOJQJ^JaJhACJOJQJ^JaJ,<}=}M}N}O}[}\}~~riiiiiii $IfgdJkdU$$IflM0 # 3  t 0+$644 lap ytJ~~~~~~\SSSS $IfgdJkd1V$$Ifl4F j#` U  t 0+$6    44 laf4p ytJ~~~~~~^UUUH & F$IfgdA> $IfgdJkdW$$Ifl4F j#  U  t 0+$6    44 laf4p ytJ~~~~~lm;<\SSSSSSS $IfgdJkd X$$Ifl4F j#  U  t 0+$6    44 laf4p ytJ<=>I\]to_KK t"dd$If[$\$gdJdd$If[$\$gdAgdAkdY$$Ifl0 # 3  t 0+$644 lap ytJ>I\]^_almqs ܁[]klmnĒscUNNUN h;hZh;hZ\^JnH tH h;hZ5\^JnH tH h;hZ^JnH tH  hchZ h}hZhZhchZ5hT)h\0J6CJaJhT)h6CJaJhT)h\6CJaJhj~h\ h\CJhA hShAhShA0J26CJ]aJhA0J26CJ]aJhShA56]^_`abcdef`[VVQQQQQgd\gd]LgdAkdY$$Ifl0 # x @@ t0#644 l` alpytA fghijkl $IfgdfigdT)gd\ ݁ށrii[[[i $7$8$H$Ifgdfi $IfgdfikdZ$$Ifl0 " W  t 0O#644 lap ytzRށlmn,kd*[$$Ifl0 " W  t 0O#644 lap ytzR $7$8$H$Ifgdfi & F 8nnW$7$8$H$If^n`Wgd< & F 8nnW$If^n`Wgd<n.Ոֈ׈Ukd[$$IflC0 " W  t 0O#644 lap ytzR $IfgdzR !$Ifgdfi $Ifgdfi &*TVtx҅7<>L^an<B_g҈ԈՈֈ׈؈ ghijxﷱ}y}}hZ h}KhZh}KhZ6h}KhZ5hchZ5 hZ5 hchZhUhzR^J hZ^JhUhZ^J#h7<h7<CJH*OJQJ^JaJhZCJOJQJ^JaJhJCJH*OJQJ^JaJ hUhZCJOJQJ^JaJ/׈ghijxQkd|\$$Ifl4F j"` y  t 0O#6    44 laf4p ytzR $Ifgdfi ljȉɉ։׉؉{|}~ۊ݊ފߊ QRST\]^_aʋˋ˼hShQ0J26CJ]aJhZ0J26CJ]aJ hZ56hShZ56hZ5CJaJheChZ^J hzR^J hZ^J hZ5h}KhZ6h}KhZ5hchZ5 hchZ h}KhZhZ1ȉɉ׉\SSSF & F$IfgdA> $Ifgdfikdj]$$Ifl4F j"  y  t 0O#6    44 laf4p ytzR׉؉|ZQQQQQQ $Ifgdfikdb^$$Ifl4F j"  y  t 0O#6    44 laf4p ytzR|}~܊݊ZQQQQ $Ifgdfikd^_$$Ifl4F j"` y  t 0O#6    44 laf4p ytzR݊ފߊ\SSSF & F$IfgdA> $IfgdfikdL`$$Ifl4F j"  y  t 0O#6    44 laf4p ytzR RZQQQQH $IfgdZ $IfgdfikdDa$$Ifl4F j"  y  t 0O#6    44 laf4p ytzRRSTaʋˋpk[GG t"dd$If[$\$gdQdd$If[$\$gdfigdZkd@b$$Ifl0 " W  t 0O#644 lap ytzRˋ̋͋΋ϋЋыҋӋԋ`[VVVVVVVgd\gdZkdb$$Ifl0 "  @@ t0"644 l` alpytfi ˋ̋͋ 78CŽҎԎߎFGHIWwxphapa h}KhAh}KhA6h}KhA5h(FhAB*ph h<OhAh7<CJH*aJhACJaJ hchA h}hAhAOJPJQJ^JnH tH hchA5 h'Oh]Lhjh"l6CJaJhjh=B6CJaJhjh]L6CJaJhWhZ5CJaJ hShZ$ԋՋ֋׋؋ًڋۋ܋݋ދߋgd\78C $7$8$H$IfgdJ $IfgdJgd]Lgdjgd\rii[[ $7$8$H$IfgdJ $IfgdJkdc$$Ifl0 # 3  t 0+$644 lap ytJҍriii`OA $7$8$H$IfgdJ$$7$8$H$Ifa$gdJ $IfgdJ $IfgdJkdad$$Ifl0 # 3  t 0+$644 lap ytJҍ?ŽҎӎԎd[[[[ $IfgdJkde$$Ifl0 # 3  t 0+$644 lap ytJ $7$8$H$IfgdJ FGHIWCkde$$Ifl4F j#` U  t 0+$6    44 laf4p ytJ $7$8$H$IfgdJ $IfgdJwCDEMӑԑՑܑ֑ؑ}q}qe^W hWgC56 hWgChWgCh hWgC6CJaJh h ~V6CJaJh h"l6CJaJhMh ~Vh]L hch]L hShAhShA0J26CJ]aJhA0J26CJ]aJhShA56 h}hA hA5h}KhA6h}KhA5hchA5 hchA h}KhAhASF & F$IfgdA>kdf$$Ifl4F j#  U  t 0+$6    44 laf4p ytJ $IfgdJCDEMtuQkdg$$Ifl4F j#  U  t 0+$6    44 laf4p ytJ $IfgdJ ԑrmm]I t"dd$If[$\$gdAdd$If[$\$gdAgdAkdh$$Ifl0 # 3  t 0+$644 lap ytJԑՑ֑בّؑڑۑܑ`[[SNNNNgd ~V$a$gd+gd]LkdFi$$Ifl0r p#  @@ t0#644 l` apyt7<ܑݑޑߑ&' $IfgdWgCgdWgCgd gd ~V$%&':KԒՒ֒46C`|œǓȓɓ͓SuhCw^JmHnHu hchXjr"jhXjr0JU^JmHnHuhXjr^JmHnHuhFhXjr^JmHnHuhchXjr5 h'OhXjrh 6CJaJh hW6CJaJhW h<h ~V h`!n56 h{56 hWgC56hnXhWgC56,Ւ֒45`[RMDDD $IfgdJgdXjrgdWgd ~Vkdj$$Ifl0j#R @@ t0644 l` apytWgC56CDriiiZ)$If^gdJm$ $IfgdJkdj$$Ifl0 # 3  t 0+$644 lap ytJ:;riii[[[i $7$8$H$IfgdJ $IfgdJkdk$$Ifl0 # 3  t 0+$644 lap ytJS46•͖ΖЖҖݖߖ45@ABEbds—×ΗϗЗӗԗ՗חѾ}ooooooook}hXjrhFhXjr^JmHnHuhchXjr6 hXjr5hchXjr5 hchXjr(h7<h7<B*H*PJ^JnH ph(((tH hXjrB*PJ^JnH ph(((tH %hFhXjrB*PJ^JnH ph(((tH hFhXjr^JmHnHuh7<h7<H*^JmHnHuhXjr^JmHnHu hXjr\*ЖіҖޖߖcriiiiii $IfgdJkd-l$$Ifl0 # 3  t 0+$644 lap ytJcdes՗֗ZQQQQ $IfgdJkdl$$Ifl4F j#` U  t 0+$6    44 laf4p yt0r֗חؗ<f\SSSFF & F$IfgdA> $IfgdJkdm$$Ifl4F j#  U  t 0+$6    44 laf4p yt0r$1<=Eehpۘܘޘ'ՙיFHݚޚߚǷ|uuqmquq|h%3h a hch ah a^JmHnHuhch a5h hW6CJaJhWhW6CJaJh 6CJaJ hShXjrhShXjr0J26CJ]aJhXjr0J26CJ]aJ hXjr56hShXjr56 h OhXjr hchXjrhXjrhchXjr5$fghptuژۘMDDDDD $IfgdJkdn$$Ifl4F j#  U  t 0+$6    44 laf4p yt0r h$If^hgdJۘܘݘޘrmm]II t"dd$If[$\$gdJdd$If[$\$gdJgdXjrkdo$$Ifl0 # 3  t 0+$644 lap ytJ'ՙ֙`WWWWNNN $IfgdA>gdWkdkp$$Ifl0 #  @@ t0#644 l` alpyt7<֙יߚriiiiiiS) & F$If^`gdFm$ $IfgdA>kd:q$$Ifl0 # 3  t 0+$644 lap ytA> 78E]қ՛Z[]uwߜ "$&13J^kvxҞڷ坒čą~sh%3^JmHnHu h?|\h ahch a6 h a5h7<^JmHnHuh7<h7<H*^JmHnHuh a^JmH sH hRFh a^JmH sH hch a5h?|\h a^JmHnHu hch ah ah a^JmHnHuh!.7h a5^JmHnHu,[\]uvwSkdq$$Ifl0 # 3  t 0+$644 lap ytA> $IfgdA>) & FW$If^`WgdFm$ $%&23Ԟ՞ikdr$$Ifl0 # 3  t 0+$644 lap ytA> $IfgdA> ҞӞ՞֞ YZ[imnowz{ßҟ/01>CEGRTk > bcdfٹٹݴݬٗΗΗِݹى hvh a hg h ahJJhh a^JmHnHu hJJhh ahch a6 h a5 h@,h a h@,h :> h?|\h ah a^JmHnHuh ahch a5 hch ahh aB*phh aB*ph6՞֞מXZZQQQQ $IfgdA>kd=s$$Ifl4F j#` U  t 0+$6    44 laf4p yt0rZ[\in\SSF & F$IfgdA> $IfgdA>kd+t$$Ifl4F j#  U  t 0+$6    44 laf4p yt0rnow{/0ZQQQQ $IfgdA>kdu$$Ifl4~F j#  U  t 0+$6    44 laf4p yt0r01EFGST riiiiiii $IfgdA>kdv$$Ifl0 # 3  t 0+$644 lap ytA> ZQQQQ $IfgdA>kdv$$Ifl4F j#` U  t 0+$6    44 laf4p yt0r\SSF & F$IfgdA> $IfgdA>kdw$$Ifl4F j#  U  t 0+$6    44 laf4p yt0rcZQQQQ $IfgdA>kdx$$Ifl4F j#  U  t 0+$6    44 laf4p yt0rcdefs{|rmm]II t"dd$If[$\$gdA>dd$If[$\$gdA>gd akdy$$Ifl0 # 3  t 0+$644 lap ytA>fnopqs{|}Ȣmo|?AY[Ԥޤ@BCEytttmem^^ h(hC:h7<h7<H* h;|hC:h;|hC:^JmHnHuhC: hchC:hC:^JmHnHuhchC:5 hC:hC:hABMhXjr6CJaJhWh 6CJaJ h ah ah a hSh ahSh a0J26CJ]aJh a0J26CJ]aJ h a56hSh a56$|}~`[[[[RMHgdC:gdABMgdWgd akdOz$$Ifl0 "  @@ t0"644 l` alpytA>Ȣmno|}>@ikd{$$Ifl0 # 3  t 0+$644 lap ytA> $IfgdA>@AYZ[DEriiiiiii $IfgdA>kd{$$Ifl0 # 3  t 0+$644 lap ytA>y~`abq$&'/24ۨܨݨߨĽѹѹѹٹohShC:0J26CJ]aJhC:0J26CJ]aJ hC:56hShC:56 hC:^J h@,hC:hQhhC:B*phhC: h?|\hC:hchC:6 hC:5hchC:5 hchC:hC:^JmHnHu hC:H* h(hC:h7<h7<H**`ariiiiiii $IfgdA>kdl|$$Ifl0 # 3  t 0+$644 lap ytA>abcqZQQQQ $IfgdA>kd!}$$Ifl4F j#` U  t 0+$6    44 laf4p yt0r%&\SSSF9 h$If^hgdA> & F$IfgdA> $IfgdA>kd~$$Ifl4F j#  U  t 0+$6    44 laf4p yt0r&'/34ۨܨZQQQCC $7$8$H$IfgdA> $IfgdA>kd~$$Ifl4F j#  U  t 0+$6    44 laf4p yt0rܨݨިߨrmm]II t"dd$If[$\$gdA>dd$If[$\$gdA>gdC:kd$$Ifl0 # 3  t 0+$644 lap ytA>`[RMMMMMgd gdXjrgdC:kd$$Ifl0 #  @@ t0#644 l` alpytABM tWXϫ߫#'(RûðwseWehWgCCJOJQJ^JaJhMCJOJQJ^JaJhMhhMCJaJh:CJaJhP:Eh$ICJaJhP:Eh}CJaJh$ICJaJh}CJaJhAXh}CJaJhS<CJaJhSCJaJh!MCJaJh`!nhSCJaJhi*CJaJh ~V h hC:h hC: hShC:78WXT 7$8$H$gdMgdMgd:gd: & FgdA>gd*B<gd8mgdABMgd ~Vgd TQRlͯίʱ˱ٱڱmnc^cgdjZ & FgdA> & FgdA>gd%m^gd%m^gdjZgd"T $a$gd: & F7$8$H$gdA> 7$8$H$gdMRͯίϯɱʱ˱̱ٱڱøviv_RLChugshZzCJ hMCJh1gh%m^CJ^JaJhZzCJ^JaJh`!nhMtCJ^JaJh`!nhmCJ^JaJh`!nh`!nCJ^JaJh`!nhZzCJ^JaJhhZzCJ^JaJhhZz5CJ^JaJhZzhZzCJaJhugshZzCJaJhMCJaJhq:CCJaJ hXjrhXjrCJOJQJ^JaJ hXjrhMCJOJQJ^JaJγܳ#$%&'NOõڵ$%&'(>?ͶӶԶQwlwe^ZUJhZzh%CJaJ hZz5h=H h=Hh"T h"ThZzh=Hh 2CJaJh=HhZzCJaJh%CJaJhZzhZzCJaJhZzhZz5CJaJhugshZzCJaJhMCJaJhh%m^CJ^JaJh"TCJ^JaJhZzCJ^JaJhy CJ^JaJh%CJ^JaJhhZzCJ^JaJh_lCJ^JaJײ\]$%&NOa%&'>? & FgdA>5^5gd%m^ & FgdA>gd%m^^gd%m^^gd"T & FgdA> & FgdA>gdjZ & FgdA>QŸƸǸN{kdy$$Ifl0j#7 t0644 layte x$Ifgde & Fe$If^e`gdegd7<gd%m^ & FgdA>QVW¸øĸǸEFH}ֺ׺غٺ?Aɾwlllal]a]hHzqhehHzqCJaJheh7<CJaJ heh7<0JCJaJmH sH %jheh7<CJUaJmH sH heh7<CJaJmH sH h7<h+CJaJh0CJaJhMh+CJaJhMhvfCJaJhMhS<CJaJhMhykCJaJ hJhZzhZzhZzCJOJQJaJǸFGHyd & Fe$If^e`gde{kd$$Ifl0j#7 t0644 layte x$Ifgde}od x$Ifgde & Fe$If^e`gde{kd$$Ifl0j#7 t0644 layte}~׺od x$Ifgde & Fe$If^e`gde{kd;$$Ifl0j#7 t0644 layte׺غٺ?od x$Ifgde & Fe$If^e`gde{kdу$$Ifl0j#7 t0644 layte?@Aۻod x$Ifgde & Fe$If^e`gde{kdg$$Ifl0j#7 t0644 layteAڻۻݻŽǽнѽӽ"#%aߵn`TC`C hehHzqCJ^JaJmH sH hehHzqCJ\aJhehHzqCJ\]aJ-hehHzq0J0B*CJ^JaJmH ph333sH 0hehHzq0J/6B*CJ^JaJmH ph333sH -hehHzq0J.B*CJ^JaJmH ph333sH -hehHzq0J-B*CJ^JaJmH ph333sH %hehHzqB*CJKH$^JaJph333hHzqhehHzqCJaJ!hehHzqB*CJ^JaJph***ۻܻݻod x$Ifgde & Fe$If^e`gde{kd$$Ifl0j#7 t0644 layteѽod x$Ifgde & Fe$If^e`gde{kd$$Ifl0j#7 t0644 layteѽҽӽ#od x$Ifgde & Fe$If^e`gde{kd)$$Ifl0j#7 t0644 layte#$%od x$Ifgde & Fe$If^e`gde{kd$$Ifl0j#7 t0644 layteod x$Ifgde & Fe$If^e`gde{kdU$$Ifl0j#7 t0644 laytecod x$Ifgde & Fe$If^e`gde{kd$$Ifl0j#7 t0644 layteabce$),LMN89BCEFH̻̪̙s̙s̙sbbb hehHzq0J$CJaJmH sH hehHzq0JCJaJmH sH )jhehHzq0J'CJUaJmH sH hehHzq0J'CJaJmH sH hehHzq0J&CJaJmH sH hehHzq0J%CJaJmH sH hehHzq0J(CJaJmH sH hHzq hehHzqCJ^JaJmH sH hehHzqhf/CJaJ&cdeFod x$Ifgde & Fe$If^e`gde{kd$$Ifl0j#7 t0644 layteFGH5od x$Ifgde & Fe$If^e`gde{kd$$Ifl0j#7 t0644 layte*+12457D#$JKLMO︴淪vk_kNk hehABM0J'CJaJmH sH hehHzqCJ]aJhehHzqCJaJ hehHzq0J$CJaJmH sH hehHzq0JCJ^JaJ!jhehHzqCJU^JaJhehHzqCJ^JaJhHzq hehHzq0J(CJaJmH sH hehHzq0JCJaJmH sH )jhehHzq0J'CJUaJmH sH hehHzq0J'CJaJmH sH 567Mod x$Ifgde & Fe$If^e`gde{kd$$Ifl0j#7 t0644 layteMNOod x$Ifgde & Fe$If^e`gde{kdC$$Ifl0j#7 t0644 layteod x$Ifgde & Fe$If^e`gde{kdي$$Ifl0j#7 t0644 layteod x$Ifgde & Fe$If^e`gde{kdo$$Ifl0j#7 t0644 layte568GHIJKLMNOPǸݪٟ٘ykZH#hf/B*CJOJQJ^JaJph!h8mh\zLB*CJ^JaJphhhB*CJ^JaJphh<CJaJh?hBCJaJmH sH h+CJaJ h7<h7<hehABMCJaJhehHzq6CJ]aJhehHzqCJaJmH sH #hehHzqCJ^JaJmHnHuhHzqhehHzqCJaJ-hehHzqB*CJPJ^JaJnH ph(((tH 6o_x$7$8$H$Ifgde & Fe$If^e`gde{kd$$Ifl0j#7 t0644 layte678o_x$7$8$H$Ifgde & Fe$If^e`gde{kd$$Ifl0j#7 t0644 layteod x$Ifgde & Fe$If^e`gde{kd1$$Ifl0j#7 t0644 layteHod x$Ifgde & Fe$If^e`gde{kdǍ$$Ifl0j#7 t0644 layteHIJKLMNOPwni\\KV7$8$H$^`Vgdf/ V7$8$H$`Vgdf/)gd<e^egdB$a$gd+gd7<{kd]$$Ifl0j#7 t0644 laytePRSTUZ[\]jstuvjkź}yk`\TLTDLhk'CJaJhCJaJhHCJaJhHhH56CJaJh hH56CJaJhj*h0hH6CJ]hJhH6CJ hH6CJhJhH6CJ]hH6CJ]hXphGIXCJaJhXphS<CJaJhXphHCJaJ hf/hhCJOJQJ^JaJ hf/hf/CJOJQJ^JaJhf/CJOJQJ^JaJPSUXZjjk _xxgdk'gdk'gdgdHgdHgdj*gdHgd%m^ 7$8$H$gdf/ l7$8$H$gdf/ @ gdf/ dgdf/ 9u_r GT 93\e.´״צ•~q~q~q~g~g~\~\hj*5CJ^JaJh;gCJ^JaJhJhj*CJ^JaJhj*CJ^JaJh8hCJ^JaJhHh=HhCJ^JaJh=Hh5CJ^JaJhJh5CJ^JaJhCJaJhJhk'CJ^JaJhJhCJ^JaJhCJ^JaJh h56CJaJh=H$_G -.rs'()*+gdGIX & FgdA>xgdgdgdj* & FgdA> & Fmx`mgdA> & FxxgdA>#&'(;@ABHIRSTU\yĻtf[PFhCJ^JaJh5CJ^JaJh5CJ^JaJhJh5CJ^JaJh0hGIX6CJ] hs6CJ h?6CJhJhGIX6CJ hGIX6CJ hvf6CJhJhGIX6CJ]hm6CJ]h;g6CJ]hZz6CJ] h;gh;gh=Hh;gh:f6CJ] hj*hj*hCJ^JaJhj*CJ^JaJ+,-./0123456789:;<=>?@BCDEFG gd=Hgd;ggdGIXGHI$& #$/Ifb$gd<$a$gdGIXgdGIXgd;g gd=H@....$& #$/Ifb$gd<kd$$IflF 4$D \ \  t 6 0$6    44 lae4pyt=H<ecQQQQ$& #$/Ifb$gd<kd؏$$IflF 4$D \ \ t 6 0$6    44 lae4yt=H<Bdef-./0b?@Ab4:bcd?defطhTCJ^JaJhSCJ^JaJhsRCJ^JaJhJhSCJ^JaJhSCJ^JaJhtLCJ^JaJhCJ^JaJhCJ^JaJAef~cQQQQ$& #$/Ifb$gd<kdv$$IflF 4$D \ \ t 6 0$6    44 lae4yt=H/cQQQ$& #$/Ifb$gd<kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt=H/0H^cQQQ$& #$/Ifb$gd<kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt=HcQQQ$& #$/Ifb$gdSkdP$$IflF 4$D \ \ t 6 0$6    44 lae4yt=H@cQQQ$& #$/Ifb$gd<kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt=H@ALbcQQQQ$& #$/Ifb$gd<kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt=HcQQQ$& #$/Ifb$gd<kd*$$IflF 4$D \ \ t 6 0$6    44 lae4yt=H4ccQQQQ$& #$/Ifb$gd<kdȔ$$IflF 4$D \ \ t 6 0$6    44 lae4yt=HcdtcQQQ$& #$/Ifb$gd<kdf$$IflF 4$D \ \ t 6 0$6    44 lae4yt=HcQQQ$& #$/Ifb$gd<kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt=H9ecQQQ$& #$/Ifb$gd<kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt=HefvcQQQQ$& #$/Ifb$gd<kd@$$IflF 4$D \ \ t 6 0$6    44 lae4yt=H*+,]gp|}~OQwyz{ 39:;<=cuh!55CJ^JaJh!5h7hyfCJ^JaJhCJ^JaJhJhCJ^JaJhJhxCJ^JaJh 2CJ^JaJhxCJ^JaJhSCJ^JaJhB*CJ^JaJphhCJ^JaJhCJ^JaJhCJ^JaJ++cQQQ$& #$/Ifb$gd<kdޗ$$IflF 4$D \ \ t 6 0$6    44 lae4yt=H+,=W}cQQQ$& #$/Ifb$gd<kd|$$IflF 4$D \ \ t 6 0$6    44 lae4yt=H}~cQQQ$& #$/Ifb$gd<kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt=HcQQQ$& #$/Ifb$gd<kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt=HcQQQ$& #$/Ifb$gd<kdV$$IflF 4$D \ \ t 6 0$6    44 lae4yt=H/IzcQQQ$& #$/Ifb$gd<kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt=Hz{cQQQ$& #$/Ifb$gd<kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt=HcQQQ$& #$/Ifb$gdkd0$$Ifl(F 4$D \ \ t 6 0$6    44 lae4yt=H#3:cQQQ$& #$/Ifb$gdkdΜ$$IflF 4$D \ \  t 6 0$6    44 lae4ytyf:;<=BCOccaaOOOO$& #$/Ifb$gd!5kdz$$Ifl'F 4$D \ \ t 6 0$6    44 lae4ytyfcdq@...$& #$/Ifb$gd!5kd$$IflF 4$D \ \  t 6 0$6    44 lae4pyt!5cd [\]_ !"#IJź|pbWLh;g5CJ^JaJh;g5CJ^JaJhJh;g5CJ^JaJh0h;g6CJ] hM6CJhJh;g6CJ h;g6CJhJh;g6CJ]h;g6CJ]hJhGIXaJhhhVhCJaJhVhCJ^JaJhVCJ^JaJh!5h!5CJ^JaJh!5CJ^JaJh!55CJ^JaJcQQQ$& #$/Ifb$gd!5kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt!5 cQQQ$& #$/Ifb$gd!5kd$$IflF 4$D \ \ t 6 0$6    44 lae4yt!5 2[cQQQ$& #$/Ifb$gd!5kd9$$IflF 4$D \ \ t 6 0$6    44 lae4yt!5[\]"caTTOaaFgd%m^gd & #$/b$gdkdנ$$IflF 4$D \ \ t 6 0$6    44 lae4yt!5"#()5I$& #$/Ifb$gd$a$gd;gIJX>,,,$& #$/Ifb$gdkdu$$Ifl4F 4$D \ \  t 6 0$6    44 lae4pytJOP;<Hv23456ABKMNtqd] h06CJh 6CJOJQJ]h0h06CJOJQJ]hJh06CJ]h06CJ]h0 h;gaJhsUh;g56CJaJh2hgCJaJhCJaJhbCJaJh2h2CJaJh;ghMCJ^JaJhsUCJ^JaJh;gCJ^JaJh;gCJ^JaJ$cQQQ$& #$/Ifb$gdkd]$$IflF 4$D \ \ t 6 0$6    44 lae4ytcQQQ$& #$/Ifb$gdkd$$IflF 4$D \ \ t 6 0$6    44 lae4yt<OcQQQ$& #$/Ifb$gdkd$$IflF 4$D \ \ t 6 0$6    44 lae4ytOP^~cQQQ$& #$/Ifb$gdkd7$$IflF 4$D \ \ t 6 0$6    44 lae4ytcQQQ$& #$/Ifb$gdkdդ$$IflF 4$D \ \ t 6 0$6    44 lae4ytcQQQ$& #$/Ifb$gdkds$$IflF 4$D \ \ t 6 0$6    44 lae4yt4;cQQQ$& #$/Ifb$gdkd$$IflF 4$D \ \ t 6 0$6    44 lae4yt;<HwcQQQ$& #$/Ifb$gdkd$$IflF 4$D \ \ t 6 0$6    44 lae4yt345c^^JJAgd0$`]^``a$gdVgd;gkdM$$IflF 4$D \ \ t 6 0$6    44 lae4ytt~ @AwxBC-.bc?@stuɾyh2h0CJaJh0h0CJ^JaJhBS h0CJ^JaJ)hBS h0CJ^JaJfHq h0CJ^JaJh05CJ^JaJh05CJ^JaJhJh05CJ^JaJh0h06CJ] h06CJhJh06CJ.$& #$/Ifb$gd0$a$gd0 >,,,$& #$/Ifb$gd0kd$$Ifl4F $D   t 6 0$6    44 lae4pyt0 <@cQQQ$& #$/Ifb$gd0kd$$IflF $D  t 6 0$6    44 lae4yt0@AQpwcQQQ$& #$/Ifb$gd0kd$$IflF $D  t 6 0$6    44 lae4yt0wxcQQQ$& #$/Ifb$gd0kd9$$IflF $D  t 6 0$6    44 lae4yt0cQQQ$& #$/Ifb$gd0kd$$IflF $D  t 6 0$6    44 lae4yt0cQQQ$& #$/Ifb$gd0kd$$IflF $D  t 6 0$6    44 lae4yt0$=BcQQQ$& #$/Ifb$gd0kd=$$IflF $D  t 6 0$6    44 lae4yt0BCO~cQQQ$& #$/Ifb$gd0kd$$IflF $D  t 6 0$6    44 lae4yt0cQQQ$& #$/Ifb$gd0kd$$IflF $D  t 6 0$6    44 lae4yt0cQQQ$& #$/Ifb$gd0kdA$$IflF $D  t 6 0$6    44 lae4yt0(-cQQQ$& #$/Ifb$gd0kd$$IflF $D  t 6 0$6    44 lae4yt0-.<[bcQQQ$& #$/Ifb$gd0kd$$IflF $D  t 6 0$6    44 lae4yt0bcucQQQ$& #$/Ifb$gd0kdE$$IflF $D  t 6 0$6    44 lae4yt0cQQQ$& #$/Ifb$gd0kd$$IflF $D  t 6 0$6    44 lae4yt0cQQQ$& #$/Ifb$gd0kd$$IflF $D  t 6 0$6    44 lae4yt0&;?cQQQ$& #$/Ifb$gd0kdI$$IflF $D  t 6 0$6    44 lae4yt0?@OnscQQQ$& #$/Ifb$gd0kd$$IflF $D  t 6 0$6    44 lae4yt0stu !"c^^YYYYYYYgd;ggd0kd$$IflF $D  t 6 0$6    44 lae4yt0 (12456Y\ȿwhwdwVwD#jh]h r|5UmHnHujh r|UmHnHuh r|jh r|5UmHnHuh]h r|5 jhh r|UmHnHuh7mh r|6 h"T6 h r|6hi h r|6h06CJ]h0h r|6CJ]h06CJ]h0h06CJ]h"T6CJ]h0hm6CJ]h;gh2h0CJaJh0CJaJ"#$%&'( & F $IfgdA> $$Ifa$gd $Ifgdgd r| $]a$gdV$`]^``a$gdVgd;g{{{{{{{{{o $$Ifa$gd $IfgdzkdM$$Ifl0%04 t0d&644 la -123\ $LMUjqu}*,.2357Nǻǯjh r|UmHnHu hh r| h r|5hh r|5h[h r|hV hXh r|#jh]h r|5UmHnHujh r|5UmHnHuh]h r|5> wnnnnnnn $Ifgdzkdݴ$$Ifl0%04 t0d&644 la & F $IfgdA> tM]TT $Ifgdzkdm$$Ifl0%04 t0d&644 la & F $IfgdA>$If^`gd0 $Ifgd0 +,/0c|kd$$Ifli0%04 t0d&644 la & F $IfgdA> $Ifgd0 $Ifgd 0124589NIJKezkd$$Ifl0%04 t0d&644 la & F $IfgdA> $Ifgd0 $Ifgd (GKLU_g %Y}'(*wxy~ļĴĭwf jhh r|UmHnHuh r|h r|5CJaJh0h r|6CJ]h0hm6CJ]h"T6CJ]h06CJ] h4h r|hVCJaJh^CJaJhmh r|CJaJhV h3m1h r| h r|5jh r|UmHnHuh]h r|5h r| hh r|%KMNOPQRgezkd!$$Ifl0%04 t0d&644 la & F $IfgdA> $Ifgd0 $Ifgd wxz{|}~0 & F $IfgdA> $Ifgd0 $Ifgdgd r|$`]^``a$gdVxgdV ~/0"5DFGHJKOPRpx~ߡߡߡߡߡߡߡ}ߡߡ#jh]hMt5UmHnHu#jh]h`6\5UmHnHu hXh r|#jh]h r|5UmHnHujhq:C5UmHnHujh r|UmHnHuhQ[h r|5h r| h r|5h]h r|5jh r|5UmHnHu1{{{{{{{{{rr $Ifgd0 $Ifgdzkd$$Ifl0%04 t0d&644 la 1EFIJLMNOQwnnnnnnn $IfgdzkdA$$Ifl0%04 t0d&644 la & F $IfgdA> QRx*JKOPelc $Ifgd|kdѸ$$Ifl0%04 t0d&644 la & F $IfgdA> $Ifgd0 IJKLNOSe #$Sfw4Hi½ hAn-h r| h3m1h r| hh r|#jh]h r|5UmHnHujhq:C5UmHnHu h r|5h]h r|5mHnHujh r|5UmHnHujh r|UmHnHuh]h r|5 hh r|h r|3eullllllll $Ifgd|kde$$Ifl0%04 t0d&644 la & F $IfgdA> $neeeeeee $Ifgdzkd$$Ifl0%04 t0d&644 la & F$IfgdA> $Ifgd0 Dclgggg^xgd%m^gd r||kd$$Ifl0%04 t0d&644 la & F $IfgdA> $Ifgd0 >ABCDENOPcdOV ż{m`mV{h<CJ^JaJhIOh<CJ^JaJh<CJ^JaJmH sH h<h<5CJ^Jh<CJaJh<CJaJmH sH h<h<5CJaJhJhGIX^JhwwhGIX6CJ]hq:C6CJaJh"T6CJaJhZzhZz6CJaJhm h4h r|hVCJaJhmh r|CJaJh r|hMO !cdb}kd$$Ifl0 $g  t0$644 layt`6\ $Ifgdfmi $Ifgd<gdGIXtg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 layt`6\tg $Ifgdfmi $Ifgd<}kde$$Ifl0 $g  t0$644 layt`6\Ntg $Ifgdfmi $Ifgd<}kd $$Ifl0 $g  t0$644 layt`6\NOVtg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 layt`6\!tg $Ifgdfmi $Ifgd<}kdQ$$Ifl0 $g  t0$644 layt`6\ !8Edm2S^uy×{f{f{f{Mf0hi*0J"6CJ\]^JaJfHq )hi*hi*CJ^JaJfHq 6hi*hi*0J"6CJ\]^JaJfHq hi*hi*5CJaJh<B*CJ^JaJph#h<B*CJ^JaJmH phsH h<CJaJ hfwh<CJOJQJ^JaJh<CJ^JaJhfwh<CJ^JaJh<h<5CJaJ7tg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 layt`6\78Etg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 layt`6\tg $Ifgdfmi $Ifgd<}kd=$$Ifl0 $g  t0$644 layt`6\ctg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 layt`6\cdmtb$7$8$H$Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 layt`6\2tg $Ifgdi* $Ifgd<}kd)$$Ifl0 $g  t0$644 layt`6\123S+CO7ƺΡp_N>h<h<5CJaJmHsH hfwh<CJOJQJ^JaJ!hfwh<B*CJ^JaJph!hfwhbB*CJ^JaJph!hfwh<B*CJ^JaJphhfwh<B*CJ^Jphhfwh<CJ^Jh<h<5CJ^JaJh<h<5CJ^Jh<CJaJh<h<5CJaJhi*CJaJhi*hi*CJaJ#hi*CJ^JaJfHq 23Stg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 layt`6\tg $Ifgdfmi $Ifgd<}kdq$$Ifl0 $g  t0$644 layt`6\tg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 layt`6\tg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 layt`6\7tg $Ifgdfmi $Ifgd<}kd]$$Ifl0 $g  t0$644 layt`6\tt $Ifgd:}kd$$Ifl0 $g  t0$644 layt`6\*9:456U O(H dk  : O     e o     ! ָumh<B*phh<B*CJaJphh<h<5CJaJmHsHh<CJaJh<h<5CJaJhABMCJaJhi*hABMCJaJ:hi*hi*B*CJOJQJ^JaJfHph q h<hABM5CJaJhABM5CJaJhOCJaJh<hO5CJaJ))tt $Ifgd:}kd$$Ifl0 $g  t0$644 layt`6\)*:5tt $Ifgd:}kdI$$Ifl0 $g  t0$644 layti*56Utg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzRtg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzR O'tg $Ifgdfmi $Ifgd<}kdC$$Ifl0 $g  t0$644 laytzR'(Htg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzRtg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzRtg $Ifgdfmi $Ifgd<}kd/$$Ifl0 $g  t0$644 laytzR ctg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzRcdktg $Ifgdfmi $Ifgd<}kdw$$Ifl0 $g  t0$644 laytzR tg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzR   9 tg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzR9 : O  tg $Ifgdfmi $Ifgd<}kdc$$Ifl0 $g  t0$644 laytzR    tg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzR   d tg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzRd e o  tg $Ifgdfmi $Ifgd<}kdO$$Ifl0 $g  t0$644 laytzR    tg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzR ! @ $ tg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzR! 2 @ $ % 8 k m n  EVWX$>Nwk]N?hfwhbB*CJ^Jphhfwh<B*CJ^Jphh<h<5CJ^JaJh<h<5CJ^JhOCJ^JaJhfwhOCJ^JaJ hfwhOCJ^JaJmH sH h<hO5CJ^JaJh<hO5CJ^JhOCJaJh<hO5CJaJhi*CJaJh<CJaJhVh<CJ^JaJh<h<5CJaJh*B5CJaJ$ % 8 k l m tggg $Ifgdfmi $Ifgd<}kd;$$Ifl0 $g  t0$644 laytzRm n  Dtt $Ifgd:}kd$$Ifl0 $g  t0$644 laytzRDEXtt $Ifgd:}kd$$Ifl0 $g  t0$644 laytzR$tg $Ifgdfmi $Ifgd<}kd'$$Ifl0 $g  t0$644 laytzRtg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzRN@[  z{|34Hp˳ק˘x˳om˳Uh<6CJaJ hfwh<CJOJQJ^JaJhP:Eh<CJ^JmH sH hfwh<CJ^JmH sH h<h<5CJ^Jh<B*CJ^JaJphh<CJ^JaJh<h<5CJaJh<CJaJ hfwh<CJOJQJ^JaJhfwh<B*CJ^Jph%tg $Ifgdfmi $Ifgd<}kdo$$Ifl0 $g  t0$644 laytzR?re $Ifgdfmi $Ifgd<kd$$Ifl0 $g  t0$644 laytzR?@[tb$7$8$H$Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzRtg $Ifgdfmi $Ifgd<}kd_$$Ifl0 $g  t0$644 laytzR {tg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzR{|tg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzR3tb$7$8$H$Ifgdfmi $Ifgd<}kdK$$Ifl0 $g  t0$644 laytzR34Hotg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzRoptg $Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzRtg $Ifgdfmi $Ifgd<}kd7$$Ifl0 $g  t0$644 laytzR study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer.TrastuzumabA manufactured antibody (a small part of our immune defences) which is attracted to the HER2 receptor on some breast cancers. It signals to the immune system to destroy these cells.Tumour/sA lump or mass of cells which can be either benign (not cancerous) or malignant. UltrasoundAn imaging test that bounces sound waves off tissues and converts the echoes into pictures.Wide excisionThe removal of the breast lump together with some surrounding tissue.  This is the date where mastectomy is agreed as the treatment option by consultation between the patient and the clinician.  The exclusion of patients with M1 disease is not intended to imply that mastectomy and immediate reconstruction is not a valid treatment option for patients with metastatic disease. The development group recommend that all patients are discussed on an individual basis to determine the most appropriate treatment.  The exclusion of patients with M1 disease is not intended to imply that mastectomy and immediate reconstruction is not a valid treatment option for patients with metastatic disease. The development group recommend that all patients are discussed on an individual basis to determine the most appropriate treatment.  The validated tool PREDICT (version 2.1) should be used to calculate predicted benefit of adjuvant chemotherapy.  At the time of publication, Oncotype Dx is the only genomic test in use within NHSScotland for breast cancer.  Details of the genomic assay tests that are currently measured within this QPI are outlined within the associated measurability document. At the time of publication, Oncotype DX is the only genomic test in use within NHSScotland for early breast cancer.     PAGE 5 Breast Cancer QPI Formal Review Engagement Document v4.0 (26th April 2019) Development of nationally agreed QPIs, dataset and measurability Data collection, analysis, reporting and publication Satisfactory performance Expert Review Group convened to review results Where required, if significant variance identified Improvement Support If progress acceptable Monitoring If progress not acceptable Action if failure to progress improvement Regional implementation of nationally agreed QPIs Data collection, analysis, reporting and publication Satisfactory performance Results reviewed by RCAGs If progress acceptable Monitoring Improvement Support If progress not acceptable Action if failure to progress improvement Qtb$7$8$H$Ifgdfmi $Ifgd<}kd$$Ifl0 $g  t0$644 laytzRQR[$klmn'()*cdefhJǿǶ~t~tih'hT)mH sH hT)^JmH sH  hT)^J h1>2hT)h\chT)mH sH hT)0J4B*ph"""hT)mH sH hT)jhT)0JUhJhGIX^Jhi*CJaJh`!nCJaJh<h`!n5CJaJh<CJaJh<B*CJ^JaJphh>B*CJ^JaJph%QR[ttt $Ifgd`!n}kd$$Ifl0 $g  t0$644 laytzRtt $Ifgd`!n}kd#$$Ifl0 $g  t0$644 laytzR$jtt $Ifgd`!n}kd$$Ifl0 $g  t0$644 laytzRjkl(dKNO|ooobbUPgdXjr ^`gdzR ^`gd< r^`rgd.wggdO}kdk$$Ifl0 $g  t0$644 laytzR JKLMMNOPQSTVWYZ\]cdefg*+,FGvwоО癞烙wh=hT)5CJaJh3 hT)5hfhT)56CJaJ hT)5hChT)5 h0hT)hND0JmHnHu hT)0JjhT)0JUjhGUhGhhT)mH sH hT)mH sH hT)jhT)0JUhOhT)mH sH .OPRSUVXY[\g+,FGvwgd r|$a$gd r|h]hgd&d &`#$gdO*+]^ !K$a$gd$a$gd r|gd r|*+\]^mnw !KLMNĸĸޱhJhGIX^JhG hOhT)h`6\hT)5CJaJhi9hT)5CJaJhfhT)56CJaJhChT)5 hT)5h!XhT)5hT)hfhT)5%KLMNgdOJ 00P1h:pyf?P@P . A!"#$% DpFJIɄ^-&ίdJFIFHHC     C   TT" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?S((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((Y|$OmgѬ-er!K ֻo?M_gb:m~fu$c{3$JE8ҿe'_4W8/>c?Wf_)eoW<(nX QxNyl/ ffT'h千#) T3ZS5PV8kȺ%(үAZ=Wo3GQ(=s?ڛ /i=jkh's_LbЇ}kȿ];)`+: a*api_WgօYEKDЯ{DNnK4[73ss!w(8_MEKD?Z׋`aU?c^ zcX_^8~4()jK3jnAG%_҇\-TFHZtcc|DNnTkV_Qk);4Bi2Lc$n2:WuzG'ƽ+K"`NRTIyPWrI?~h6>) -/^G_VqHn׿5|Ku~3>_#''X %r`k_}W3'e d K Z1&V{XRPx?nf?L_ Q8 +F؇n0ȡB&M]Hҋ=?#.1Hk;GS,v櫟mo@㤸QhZV ~qbS_Uߋ<ޓki-?FG?_G1|9|I>. Fw>ѥj 77#R=A"ߵM@Aw~$V %l%£,#z]~]Yã5u^7^ON\}}Y6?cE|_`?)~Gb?P)hZt,Z'x־{_?5%_҇JߌX|ua(zÇSf N:#hUc^Wפ~q kҿ*—-0|y/ ׼M k8,ro8UNn5]Z~p sTa@9&?d@H/ FXCES^9)hy]Q $ m{?ks~?et'< M_QV~Μk7L#%+^TokZo:ZEw Kv}ԥ>USZJOc5cIvϤX )Y_Q\rϫx"<}-K }VA`Ur+A%*/ Yͩ8V_^ؙSzT8^5OZoZr _|1L'<#s2zWٵGD;XiZu0Gmmc$PW5&˫=jT((.EW1QEQEQEQEW~j?/5߶t῏O~fU/F~E񃂒:C_S XnZn1JGz վxWֹllm.na=A=uhWʏX5tڂFbF8"f/KW^o6mzdo b+r@˓¿kҿgcE񎛾XʾVbrT{WeX+Zk = kg>DRxL?4ku=NNc؎zW55eɮ+,Z'xֿ:<"^0赯/=x{km.ƚ,"Ak N7X>ʇź DYFkvב_*WwpO/|\|/_!w4όzG%WcsCwgs-,)rXrҾ-{m?7:+} \ěrr˛_c-*+TW ǜ<9@%NN3Vh%%uQEQ@Q@Q@Q@x&31^^-gɫL:{ ɫQU7*q/2A\wBB1봧d5I/*f_*MkF{Vװ=ʹrKVV+3 LD揠RUrhb?gҟi-X=(랄WҩU N.q[n%WbO.0HE;G'TQZx?E-`k_ΝEKD?ZKYF=P WK=Xp*z#LVǃ-}mkiVچYdXq70ɬz٣N;WzWE_gVN0D I3_h?3M럎5E|/}}3s}&uf?_?Fe=Aԗ/u>h_gND_c |6+: ?!՟E Q_.zDŽ|q>{{kBפ:ތ叫RCǰ"!ƅ$&A]{(?4m,JUSbЕgW JZg D]yxm̶G?z H +~6 ~7YyH}W2U~CKYJ9?>>wfhτWX@.^r}$fT'k" m' xf`M6^(嶽=%Yy'r~p+#rKo^3Aȥ׌-kӯ)hZ"i|C7ׯ?zJ*{~3a%ODi18٣N;WzWE^o^4|*Jȫk ^)k+(>%x:?Σ?v_ &JίgND_|A,o+Pt|G[l/LXSMbtv d*+sW#_T7RLzGU$,ij3ORhxΥeu0eI~|$o#]ͦEzÐ=@+Mz5E+*Ir! HA+~_Eg5 81f ?"kO( x.Id-:Kp=gx9hunDz%Q_}QEQEQE'JZ)(&_+kÏx>k+Mfխd3zڄ*r5NPiv?+;O|E~hDxߨ? ogBo$Bz^c]~W/1ًok|**4HXm1b74Sb]JN0J, ߂41-۵'SЃف؀GJߢZktu?hOKVTݻVՉ_Xv6ooQCiV:^LkXa;8Tc~wDߨ?6ytv]?*)f?,k,Z'x־!Dߨ?J]+LF.Ф*ԅdUgMQwz,=J\r=P_J߇,>xİjW^Fb\y-޲1ps{:*J٣N;WzWE_߇9xU/%߀~xÞ(_.nMJRͿ#*Ȫ،k89SSzǙ h64E?:Y$Ù[o5MF8wg3>_|; |6+4_!"lĝ zgl4𵆴ʻ#t)sIQ8xH*5#x3i9?Wo$wue?obre[y!FQ kU.GFYecTM~9D)y7zW?g?o[Ȼ'$̷sl3BW0{Ge,YD| ‹4E ώ$zR0|ÆAa‚@'$Eb*b:]ҥQQE!cQhQEW_d> R1̸'H_N1/p|Cʨ-Z$v}O] B{'<| o%~)?~+F^M9I%r7;!Xq޿NJXgK;Xg# ЊԴ#Q&ꎤS ½sȚ&^2yhI0s̥b}fg|'QʦXjrz?}o?C_ xE΍PjvT+9FPn2VhH=Z(1Z(((( R@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@|_|i[ 淶gucPsq vu?+fW^j0 DR*TWWb.3Ms?jۯ~xwcSeogYkӾ8=D-qz ad }>ҏfVN2~h}aY׿>XgꩩD&*W QUꗈ8{xg~? /K!kPYn;t,3}+3)?#fr!LFmRvL)LIx ؾ5.ysOJTϱ*Hݣղ#G<tʺgL)|'E)_-oFVʧYUK1?N|-M5s$v)u֭L&6㸉%D7Ѳz:u߆ 'u۽93n?FS׋xj'kxQ5mx;G-|$OՒsj*Z}^>Y>uKMj olP\[t}Cq)r׍?]`Xs*_ٯU"斸O`(jc=V!Yp:'=wd&Weֵ3v/{je}&X~,@~2~^L_I6[#>Fzz?0k5g?`WsJu"h~o'K k%姙+ះ]R%N ņ}k?(.0{tB%G}E.A{ٽWxJ0Uϯ[ t[4!}OҫP _㸛4ZxzŚ톏۵֡{* KݏR{Iv^Eoo<8RNrI$>!-/U1N=?x6q_kYJy~Y%ur7_{~T_q~#tyėH=6}I. #źt% M}=%?:*{[Sc7$$qpO]B+h#tH*WSIWoўbGj Ok 00{w 6\[kNJKg{#gRk _W[Aծ4*+e(H`AGJs<1XZ=w@]m՝~ oKu/~g?zg$1+XLoti_7:L|=Y!GįSAգ%lcO-|{_ xMOG2G0;⾒;St/ʳ^CN6qOJӏt?[Ю|\Nr 3wU75{il";KaV}%c?[ҧ:}"hdGbA"xz0ݎ}^Ѓ>8YYݎ'Ҿ; { $FîfǤ?}U K`#aԇ,߉5׌,6N;};,~6*!Q}ioOӾW@^nc=$Mv_!\?ӥc-~Q^#Ғk-+#GQ`Muk:c械*pFq_UxKC ~QykqSގ'~EQڿMك~ 8m6QW~¿mu4#я^>&R_%3­?WڇI?bz}%XW?OAI?mOdR}K^[?%>F~ngƑEmSƅuO?&{_ gSvq3>g[o&[CmA<~'oȓMM I.뚅B>kXm⵷mHa@ I o̻Jx.E3#]~,z.r:b;|XTy>^ۊZ+1i] T0Q6QEsEPEPEPEPEPIZ((((({"wR ݝʺ*9BJQvhΥ8UQ^/tggU')%ݹz|1¸Gp>]-|G,mw0n?u& Gh|c+ǞU꧳)؊ُN^=R7oax?1lv 2=ss_cW5?-,G#ky^}O̰=S'ib0i3M/ݟҳ??Ij?"jW}: EBW_ק|!b5Hts[@G1طSue/ٽ/KjijYoS+:6W-]|?2[ReO߫=B(?N ( ( ( ( LR@Q@Q@Q@Q@Q@Q@TW7Z[<0DF dOހ%_59l_1YC3U{#޶_~,iZwΓ\0Hlǀ1'sǂĨnކ &Tϡh5 *^IpI$ܞPZu lIJ5s s7]KkOWՎ^}EXT̩zI;9/Ɗ𗌴/,.owvѓeIw:t ::eeՙ.W~[jouk4Wʞ+| :vV}B#޷>A~E/R8uvV?1ǁ(:nކ Is/>9VhH]VSAExWۇ~/eXmL#2+#*xaОNJϖ[~J沜`'ch?!t׿f~R(:o?Vœ]ZUbIFrq[k߅R񟈤ҵwKi3-;7~wnneoS٨cmׂx^ Pk/FGr;WO\8+4jj( gE I'KE|ۿ[xkE{\jC&u+*x‚O'G{9jQEڤZ~jFqwemRֵ)Lvm-̡ 4. 8PNyG/xKKZt{fWl2 sp U'8Ŵvެ(,(`.Yn|O5Ԗifu,{/2>8Hehm-&#k)8;f~ 9)+#Ѩ??֖\,|@V8mw(G%wJ_s#m}&Nj?i1,56NNI'r3[N;ꂊ(0(((( |4tˉm,>\.6s_WKM \ƣW+=$$GB]mfʂĿGot& IHSU_os&I=a @ȅ<]G1ͨ=]O!$wD2<, GHk,J4}+N Sᆆ?-! S{FqEyO|%Gş u Mn A$J289?0FGxͱq;^*C5OxKeBK jҭ-:m"+9!vV gj0פFH\ K<* c8Gzr΍mAhb81\8?!ó'3i/ٶ]ڻ-21JOafxjio//:QrOG)f?}?| R/GPSWNE-{g}?Zx#^ڪϥ]otNQʊI)🉵T |4wv{P>5/?-?\ ^VcN4VӦaT(ˆ?_ƛ/$u>EG2Yj0T$B@#ÏV@|(|go̶krI=i1IrF>Z_? ĭݍk<̎nuqZ}aۡt/?C( ( ( ( ( (n/şGcBPŵr)GI.HEtaT̪T(ch/ٳw_J5K[VN{w\Ccխ|a%||~(𮡵.`ϗ2$wH }-O#ւdYm.__+/IF+& (TS#4T\p2@ʨpp+S_knxҪ*Z> o7Ե"53&.y#!kc:險K\\9zy'$qÞhtxh0hH˯O~R*mcNY!}(YvZ 8l`3qe\ݣ+߱*D^*n~_߳ſ t+OxHLA|pث, 7^?>Rn3+ϩc!>Xmc><.-lCX*z@_kKp>fk1:W﯄ '7D=` K4+mC?|//ӿ_܌f!?s/O*6zȿL0 &u/kkh> xo~ ծ4pԍ$.%aJ0$j~EQT1+Ԝam,]ӌ\Ic|zmW|gsfoHcH>H5C⽟M3 cOYky'A _jZ~2c63kST?Gn"_E=>©)naon0Y@Kb]xYG/:ӍGkmƪxG$]3Wu_ 4m+æ^t̄nV /?~ ~n%6d?ږ- Y1ݞqr+KLxO'MԦرa|z,j+,)cO5aR-W+ٟEsQY+W %' oһJ7\OkY?U𶣥j$ t\ҾGICxiҸ0G-ևMY)ץ%siY$V5Qo_ $>8?=7%~zOv4P-|3&W,wxO:|ڕurUA-A?Pz_>>/oZʷ")P]g*؂ }M| RÏI寱!|<Z+4ȏ "_Z+bCL/_b_m^Ee 9^ \־ %zUu V>^{duכ1X\N:;kuX|UTc=QS U<k2qxs(#SB[q^ ΃*ĺۖ!RǷ,C_&|~(;^)tj^%#+%'nH6(O|> lt.-_E'IIO0O ЕZ%eܢ+`((((+;^*m3Z,}6qlI?hM6nxM3#Q7r7Rs &?/|6-,6 zuCcĚh^E938E) -9>I^ I2^ Q V=߉~_1xV? i&S{ٙ^Et,EhǕMՙ:Pn*V}VְGmmP""Ҥ$6GP+ PE>5<_??^ާEDsmi'd~ }heg1KqfY7:WQ]YǕ۵ٚQEsώ>S]<;xO:u;d#|cr^W1G/ i^K­r]@&+nlgWE_KRд/ i:F}G 6W98 'ڤڗ<xwPo%Ιc4EP \z]^n2y#&)h8+m +M;g]JN'Y;8\w6Oo1k[xoKd=N'X"+Oi;s;2y#kXd?K'_K49[M"9A|&Z(uYN d(M(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((yDyK  _Toc7510955yDyK  _Toc7510955yDyK  _Toc7510956yDyK  _Toc7510956yDyK  _Toc7510957yDyK  _Toc7510957yDyK  _Toc7510958yDyK  _Toc7510958yDyK  _Toc7510959yDyK  _Toc7510959yDyK  _Toc7510960yDyK  _Toc7510960yDyK  _Toc7510961yDyK  _Toc7510961yDyK  _Toc7510962yDyK  _Toc7510962yDyK  _Toc7510963yDyK  _Toc7510963yDyK  _Toc7510964yDyK  _Toc7510964yDyK  _Toc7510965yDyK  _Toc7510965yDyK  _Toc7510966yDyK  _Toc7510966yDyK  _Toc7510967yDyK  _Toc7510967yDyK  _Toc7510968yDyK  _Toc7510968yDyK  _Toc7510969yDyK  _Toc7510969yDyK  _Toc7510970yDyK  _Toc7510970yDyK  _Toc7510971yDyK  _Toc7510971yDyK  _Toc7510972yDyK  _Toc7510972yDyK  _Toc7510973yDyK  _Toc7510973yDyK  _Toc7510974yDyK  _Toc7510974yDyK  _Toc7510975yDyK  _Toc7510975yDyK  _Toc7510976yDyK  _Toc7510976yDyK  _Toc7510977yDyK  _Toc7510977yDyK  _Toc7510978yDyK  _Toc7510978yDyK  _Toc7510979yDyK  _Toc7510979yDyK  _Toc7510980yDyK  _Toc7510980yDyK  _Toc7510981yDyK  _Toc7510981yDyK  _Toc7510982yDyK  _Toc7510982yDyK  _Toc7510983yDyK  _Toc7510983yDyK  _Toc7510984yDyK  _Toc7510984yDyK  _Toc7510985yDyK  _Toc7510985yDyK  _Toc7510986yDyK  _Toc7510986yDyK  _Toc7510987yDyK  _Toc7510987yDyK  _Toc7510988yDyK  _Toc7510988yDyK  _Toc7510989yDyK  _Toc7510989yDyK  _Toc7510990yDyK  _Toc7510990yDyK  _Toc7510991yDyK  _Toc7510991yDyK  _Toc7510992yDyK  _Toc7510992yDyK  _Toc7510993yDyK  _Toc7510993$$Ifl!vh#v #vx:V l @@ t0p#65 5x` alpyt7^f$$Ifl!vh#v #vx:V l @@ t0p#65 5x` alpyti$$Ifl!vh#v #v:V l @@ t0"65 5` alpyti$$Ifl!vh#v #vx:V l @@ t0p#65 5x` alpyttG$$Ifl!vh#v #vx:V l @@ t0p#65 5x` alpyttG$$If!vh#v #v3:V l  t 0+$65 53p ytfi$$If!vh#v #v3:V l  t 0+$65 53p ytfi$$If!vh#v #v3:V l  t 0+$65 53p ytfi$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p ytfi$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p ytfi$$If!vh#v #v#vU:V l4f  t 0+$6+5 55U/ / / / f4p ytfi$$If!vh#v #v3:V l  t 0+$65 53/ p ytfi$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p ytfi$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p ytfi$$If!vh#v #v#vU:V l4f  t 0+$6+5 55U/ / / / f4p ytfi$$If!vh#v #v3:V l  t 0+$65 53/ p ytfi$$Ifl!vh#v #v:V l @@ t0#65 5` alpyt0r$$If!vh#v #v3:V l  t 0+$65 53p ytfi$$If!vh#v #v3:V l  t 0+$65 53p ytfi$$If!vh#v #v3:V l  t 0+$65 53p ytfi$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p ytfi$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p ytfi$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p yt.wg$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p yt.wg$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p yt.wg$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p yt.wg$$If!vh#v #v3:V l  t 0+$65 53/ p ytfi$$Ifl!vh#v #v:V l @@ t0"65 5` alpytfi$$If!vh#v #v3:V l  t 0+$65 53p yt$$If!vh#v #v3:V l  t 0+$65 53p yt$$If!vh#v #v3:V l  t 0+$65 53p yt$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p yt$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p yt$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p yt$$If!vh#v #v3:V l  t 0+$65 53/ p yt$$Ifl!vh#v #vx:V l @@ t0#65 5x` alpytA$$If!vh#v #v3:V l  t 0+$65 53p ytfi$$If!vh#v #v3:V l  t 0+$65 53p ytfi$$If!vh#v #v3:V l  t 0+$65 53p ytfi$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p ytfi$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p ytfi$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p ytfi$$If!vh#v #v3:V l  t 0+$65 53/ p ytfi$$If!vh#v #v:V l @@ t0$65 5` apytzR$$If!vh#vD #v3:V l  t 0w#65D 53p ytfi$$If!vh#vD #v3:V l4  t 0w#6+5D 53/ p yt<$$If!vh#vD #v#vG#v3:V l4  t 0w#6+5D 55G53/ / / / / p yt<$$If!vh#vD #v#vG#v3:V l4  t 0w#6+5D 55G53/  / / / p yt<$$If!vh#vD #v3:V l  t 0w#65D 53p ytfi$$If!vh#vD #v#vU:V l4  t 0w#6+5D 55U/ / / f4p ytfi$$If!vh#vD #v#vU:V l4  t 0w#6+5D 55U/ / / / f4p yt<$$If!vh#vD #v#vU:V l4_  t 0w#6+5D 55U/ / / / f4p yt<$$If!vh#vD #v#vU:V l4  t 0w#6+5D 55U/ / / f4p ytfi$$If!vh#vD #v#vU:V l4  t 0w#6+5D 55U/ / / / f4p ytfi$$If!vh#vD #v#vU:V l4_  t 0w#6+5D 55U/ / / / f4p ytfi$$If!vh#vD #v3:V l  t 0w#65D 53/ p ytfi$$If!vh#v #v:V l @@ t0q#65 5` apytJ$$If!vh#v #v3:V l  t 0+$65 53p ytJ$$If!vh#v #v3:V l  t 0+$65 53p ytJ$$If!vh#v #v3:V lM  t 0+$65 53p ytJ$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p ytJ$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p ytJ$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p ytJ$$If!vh#v #v3:V l  t 0+$65 53/ p ytJ$$Ifl!vh#v #vx:V l @@ t0#65 5x` alpytA$$If!vh#v #vW:V l  t 0O#65 5Wp ytzR$$If!vh#v #vW:V l  t 0O#65 5Wp ytzR$$If!vh#v #vW:V lC  t 0O#65 5Wp ytzR$$If!vh#v #v#vy:V l4  t 0O#6+5 55y/ / / f4p ytzR$$If!vh#v #v#vy:V l4  t 0O#6+5 55y/ / / / f4p ytzR$$If!vh#v #v#vy:V l4  t 0O#6+5 55y/ / / / f4p ytzR$$If!vh#v #v#vy:V l4  t 0O#6+5 55y/ / / f4p ytzR$$If!vh#v #v#vy:V l4  t 0O#6+5 55y/ / / / f4p ytzR$$If!vh#v #v#vy:V l4  t 0O#6+5 55y/ / / / f4p ytzR$$If!vh#v #vW:V l  t 0O#65 5Wp ytzR$$Ifl!vh#v #v:V l @@ t0"65 5` alpytfi$$If!vh#v #v3:V l  t 0+$65 53p ytJ$$If!vh#v #v3:V l  t 0+$65 53p ytJ$$If!vh#v #v3:V l  t 0+$65 53p ytJ$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p ytJ$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p ytJ$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p ytJ$$If!vh#v #v3:V l  t 0+$65 53/ p ytJ$$If!vh#v #v:V l @@ t0#65 5` apyt7<$$If!vh#v#vR:V l @@ t0655R` pytWgC$$If!vh#v #v3:V l  t 0+$65 53p ytJ$$If!vh#v #v3:V l  t 0+$65 53p ytJ$$If!vh#v #v3:V l  t 0+$65 53/ p ytJ$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p yt0r$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p yt0r$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p yt0r$$If!vh#v #v3:V l  t 0+$65 53/ p ytJ$$Ifl!vh#v #v:V l @@ t0#65 5` alpyt7<$$If!vh#v #v3:V l  t 0+$65 53p ytA>$$If!vh#v #v3:V l  t 0+$65 53p ytA>$$If!vh#v #v3:V l  t 0+$65 53/ p ytA>$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p yt0r$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p yt0r$$If!vh#v #v#vU:V l4~  t 0+$6+5 55U/ / / / f4p yt0r$$If!vh#v #v3:V l  t 0+$65 53/ p ytA>$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p yt0r$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p yt0r$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p yt0r$$If!vh#v #v3:V l  t 0+$65 53/ / p ytA>$$Ifl!vh#v #v:V l @@ t0"65 5` alpytA>$$If!vh#v #v3:V l  t 0+$65 53p ytA>$$If!vh#v #v3:V l  t 0+$65 53p ytA>$$If!vh#v #v3:V l  t 0+$65 53/ p ytA>$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p yt0r$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / f4p yt0r$$If!vh#v #v#vU:V l4  t 0+$6+5 55U/ / / / f4p yt0r$$If!vh#v #v3:V l  t 0+$65 53/ p ytA>$$Ifl!vh#v #v:V l @@ t0#65 5` alpytABM$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#v7#v:V l t06575/ ayte$$If!vh#vD #v\ :V l  t 6 0$65D 5\ e4pyt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l( t 6 0$65D 5\ e4yt=H$$If!vh#vD #v\ :V l t 6 0$65D 5\ / e4ytyf$$If!vh#vD #v\ :V l' t 6 0$65D 5\ e4ytyf$$If!vh#vD #v\ :V l  t 6 0$65D 5\ e4pyt!5$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt!5$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt!5$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt!5$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt!5$$If!vh#vD #v\ :V l4  t 6 0$65D 5\ e4pyt$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt$$If!vh#vD #v\ :V l t 6 0$65D 5\ e4yt$$If!vh#vD #v#v :V l4  t 6 0$65D 55 e4pyt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#vD #v#v :V l t 6 0$65D 55 e4yt0$$If!vh#v0#v4:V l t0d&65054/ $$If!vh#v0#v4:V l t0d&65054/ $$If!vh#v0#v4:V l t0d&65054/ $$If!vh#v0#v4:V li t0d&65054/ $$If!vh#v0#v4:V l t0d&65054/ $$If!vh#v0#v4:V l t0d&65054/ $$If!vh#v0#v4:V l t0d&65054/ $$If!vh#v0#v4:V l t0d&65054/ $$If!vh#v0#v4:V l t0d&65054/ $$If!vh#v0#v4:V l t0d&65054/ $$If!vh#v0#v4:V l t0d&65054/ $$If!vh#v0#v4:V l t0d&65054/ $$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / yt`6\$$If!vh#vg #v:V l t0$65g 5/ / / yti*$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR$$If!vh#vg #v:V l t0$65g 5/ / ytzR5s8666666666vvvvvvvvv66666866666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@_HmH nH sH tH D`D GIXNormalOJQJ^J_HmH sH tH R@R GIX Heading 1$<@&5CJ KH \^JaJ T@T GIX0 Heading 2$<@&56CJ\]^JaJDA`D Default Paragraph FontRi@R  Table Normal4 l4a (k (No List J@J GIXpTOC 1x 56CJOJQJ\]^JaJ\@\@FpTOC 2 S"x^5CJ\^JaJmHnHu6U`6 GIX0 Hyperlink >*B*phbo!b GIXHeading 1 Char.5CJ KH OJQJ\^J_HaJ mH sH tH 8"8 GIXCaption xx5\L#L GIXTable of Figuresp^`pdoQd GIX0Heading 2 Char056CJOJQJ\]^J_HaJmH sH tH jcj GIX Table Grid7:V0borb 3GIXDefault 7$8$H$-B*CJOJQJ^J_HaJmH phsH tH 44 OHeader  9r 4 @4 1O0Footer  9r .)@. O Page NumberF@F +S0 Footnote Text^JmHsHtH@&`@ S0Footnote ReferenceH*DD H Balloon TextCJOJQJaJB' B mComment ReferenceCJaJ4@4 ,m Comment Text@j@ mComment Subject 5\V^@V 90 Normal (Web)!dd[$\$CJOJQJ^JaJ.X`!. 9@Emphasis6]FV 1F $fFollowedHyperlink >*B* ph4OA4 mixed-citation.OQ.  ref-journal&Oa& ref-vol$Oq$ nowrap8O8 element-citation@@@ =B List Paragraph )^\\ )msolistparagraph *^CJOJPJQJ^JaJH/H -0Footnote Text Char OJQJ^JFF  ~VComment Text Char OJQJ^J,O, Yh reference20O0 Yh reftitle35\<O< Yhrefseriestitle36]>O> Yhrefseriesvolume15\:: yf0 Footer Char OJQJ^JPo!P 7^fChar3.5CJ KH OJQJ\^J_HaJ mH sH tH ^1^ WgC Default Char-B*CJOJQJ^J_HaJmH phsH tH $OA$ =ilfuvdPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vc:E3v@P~Ds |w<v 5<>p^_B/mBx $0Lw.;Qm/   %& !'(Bx $0Lw.;Qm /  cccf;  L N vQ6%(w-^468T:<DHMTX\h\kp9z|>ˋwSҞfyRQAaPcJt~ ! NJN#(+48?BCFLSV[acejw]@(`0c67888:#;;<=1? CCDEeEtFFGHHIJMNEOjOdPPPxRTNUVXYYaZ[[\L`cPeMffg[h iXkl(nNo0sct*u0uvxxiyzJ{{<}~~~<]f ށn׈׉|݊Rˋԋҍԑܑ5c֗fۘ֙՞Zn0 c|@a&ܨTǸ}׺?ۻѽ#cF5M6HP_+Ge/@ce+}z:c ["IO; @wB-b?s"0KQecN7c2)5'c 9   d   $ m D?{3oQjOKN      !"$%&')*,-./01235679:;<=>@ADEGHIJKMNOPQRTUWXYZ\]^_`bdfghiklmnopqrstuvxyz{|}~9;<>\)+,.Lj2LNOQo),-/Mm.HKLNl '[uxy{=WZ[]{ 1Xruvx 7 Q T U W u  - g  . 1 2 4 R n # = @ A C a z   0 3 4 6 T y 8} '*+-K?Y\]_}zqŮɮ\fNUGn/ X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%̕XXXXXX f!t (/,R$IɄ^-&ίdJL @H 0(  l'. (    S BA$ Scotland NHS logo#" `?h  C #" `? h  C  #" `?  bB  c $D"? bB @ c $D"? bB   c $D"?h   C  #" `?  VB   C D"?h   C  #" `?  h   C  #" `? \B  S D"?VB @ C D"?VB @ C D"? h  C #" `? h  C #" `? h  C #" `?  \B  S D"?h  C #" `? \B  S D"?h  C #" `? h  C #" `?% \B  S D"?bB  c $D"?#h  C #" `?$ h  C  #" `?  h   C  #" `? h ! C !#" `? \B " S D"?\B # S D"?VB $ C D"?h % C  %#" `?  h & C  &#" `?  h ' C '#" `?  h ( C (#" `?! \B ) S D"?\B , S D"?VB - C D"?VB . C D"?"B S  ?PQVYZojknsopq!$'/(#$ t@n tZvt Jt LtL|tLkktht L]tP tL99tlt LGt =tttt (tLbbt h t  t< t%n t#Ht&a t$$t,tt"t  bt-t"t! t)L t'\ t( t.ZZtLth t tt _Hlt7510994 _Hlt7510995 _Toc275520185 _Ref275521951 _Toc282595813 _Toc282595814 _Toc283627710 _Toc283720985 _Toc283720986 _Toc283721050 _Toc283721051 _Toc283721526 _Toc284230974 _Toc284238802 _Toc444590059 _Toc7510955 _Toc450042765 _Toc7510956 _Toc450042766 _Toc7510957 _Toc450042767 _Toc7510958 _Toc275520190 _Toc282595819 _Toc283720991 _Toc283721056 _Toc283721531 _Toc284230979 _Toc284238807 _Toc450042768 _Toc7510959 _Toc450042769 _Toc7510960 _Toc444590066 _Toc7510961 _Toc275520192 _Toc282595821 _Toc283720992 _Toc283721057 _Toc283721532 _Toc284230980 _Toc284238808 _Toc303589015 _Toc275269910 _Toc284230981 _Toc284238809 _Toc297891582 _Toc444590067 _Toc7510962 _Toc444590068 _Toc7510963 _Toc275269913 _Toc297891583 _Toc444590070 _Toc7510964 _Toc297891584 _Toc444590071 _Toc7510965 _Toc297891585 _Toc444590072 _Toc7510966 _Toc297891586 _Toc444590073 _Toc444590074 _Toc7510967 _Toc444590069 _Toc444590200 _Toc297891587 _Toc297891588 _Toc444590075 _Toc7510968 _Toc297891589 _Toc444590076 _Toc7510969 _Toc297891590 _Toc444590077 _Toc7510970 _Toc297891591 _Toc444590078 _Toc444590079 _Toc7510971 _Toc444590080 _Toc7510972 _Toc450055619 _Toc7510973 _Toc7510974 _Toc392585194 _Toc453169693 _Toc7510975 _Toc392585193 _Toc7510976 _Toc7510977 _Toc7510978 _Toc444590081 _Toc7510979 _Toc444590090 _Toc7510980 _Toc444590085 _Toc7510981 _Toc444590086 _Toc7510982 _Toc444590087 _Toc7510983 _Toc444590088 _Toc7510984 _Toc282595826 _Toc283720997 _Toc283721062 _Toc283721537 _Toc284230991 _Toc284238819 _Toc275520211 _Toc282595825 _Toc283720996 _Toc283721061 _Toc283721536 _Toc284230990 _Toc284238818 _Toc297891599 _Toc444590091 _Toc7510985 _Hlt5718225 _Hlt457291846 _Hlt457291847 _Hlt5718371 _Hlt5718372 _Hlt457291860 _Hlt457291861 _Hlt5718391 _Hlt5718392 _Hlt5718396 _Hlt5718458 _Hlt5718459 _Hlt457291806 _Hlt457291807 _Toc444590092 _Toc7510986 _Toc7510987 _Toc283720998 _Toc283721063 _Toc283721538 _Toc284230992 _Toc284238820 _Toc444590093 _Toc7510988 _Toc283721000 _Toc283721065 _Toc283721540 _Toc284230994 _Toc284238822 _Toc275520213 _Toc282595827 _Toc283721001 _Toc283721066 _Toc283721541 _Toc284230995 _Toc284238823 _Toc444590094 _Toc444459324 _Toc444459696 _Toc444590097 _Toc7510989 _Toc7510990 _Toc7510991 _Toc444590095 _Toc7510992 _Toc444590096 _Toc7510993  .0&&&&&&&&&--_.k.n.n.n.n.n.n.n.n.......//00000:2:2T233344444O=@@@LLLLTTTT,],]iioo(y   **JJKKڥRRR``bbLLLLLLmyyyyyZLBBii0@@  "#!$%&'()*/012+,-.6345789:;<>=?@BCAEFDGHIJKLMNOPTQRSUVWX\YZ[]^_`abcdefghijklmnopqrs@t@u@v@w@x@y@z@{@|@}@~@@@  jj&&&&&&&,','2-2-............//00000000R2R2R23334444@@@@@@LLLTTTI]I]I]I]iooWyWy:=ߏ*66њњ qqaa$$$$$$$$$$ۥSSSaaccyyyyy===D0A      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJfbbhs};;?OYY--e*:DD)3^is0      !"#$%&'()+*,-./0123456789:;<=>?@gjjr{CCNWbb55m9BMM(19hq}0  !"#$%&'()+*,-./0123456789:;<=>?@=;*urn:schemas-microsoft-com:office:smarttags PlaceType=<*urn:schemas-microsoft-com:office:smarttags PlaceName87*urn:schemas-microsoft-com:office:smarttagsCity9@*urn:schemas-microsoft-com:office:smarttagsplace>?*urn:schemas-microsoft-com:office:smarttags PersonNameBA*urn:schemas-microsoft-com:office:smarttagscountry-region A@?A@<;@<;7@A@<;7@<;7@<;7@<;@77@<;7@A@77@<@<;<;7@<;@A@<;@<;@A@@A@:M0 1 3 4 6 7 9 : < = G   -0<,j2O-m.L[y=[Xv7 U g  2 n # A z  4 y } +?]LM0 1 = G  ,-0TTUU,V3VYYZZL_V_4`>`xx݀݀jl&LMOOE E G I  , . 0   . . / / 1 1 3 4 4 6 7 9 : < = H             & ' ' ( ( W W X X                             >>??ttuu,,-0[\KLnoLMkl&'z{01  t u , - Q R ` a e g   S T 78  JK|}TTUU,V3VYYZZL_V_4`>`xx݀݀jl&LMOOE E G I  , . 0   . . / / 1 1 3 4 4 6 7 9 : < = H             ' ' ( ( W W X X                         >>??ttuu,,-0 {HYB%@@` yyP`$ `t0e0 +3X)N+9=,R0dI7>1l]04gNC> OC^ )E/JcEBE7 $(Qh TP@t[!~\к0,O!|a[*)cZ(bVe`s\WhE{ux [wem^`mOJQJo(hHe^`OJ QJ ^J o(hHoepp^p`OJ QJ o(hHe@ @ ^@ `OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoePP^P`OJ QJ o(hHem^`mOJQJo(hHe^`OJ QJ ^J o(hHoepp^p`OJ QJ o(hHe@ @ ^@ `OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoePP^P`OJ QJ o(hHh hh^h`hH.h 88^8`hH.h L^`LhH.h   ^ `hH.h   ^ `hH.h xLx^x`LhH.h HH^H`hH.h ^`hH.h L^`LhH.e^`OJQJo(hHe^`OJ QJ ^J o(hHoepp^p`OJ QJ o(hHe@ @ ^@ `OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoePP^P`OJ QJ o(hHhhh^h`OJQJo(hHh88^8`OJ QJ ^J o(hHoh^`OJ QJ o(hHh  ^ `OJQJo(hHh  ^ `OJ QJ ^J o(hHohxx^x`OJ QJ o(hHhHH^H`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohP^P`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoepp^p`OJ QJ o(hHe@ @ ^@ `OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoePP^P`OJ QJ o(hH0^`0^Jo(() ^`hH.  L^ `LhH.  ^ `hH. x^x`hH. HL^H`LhH. ^`hH. ^`hH. L^`LhH.80^8`0^Jo(()^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L.em^`mOJQJo(hHe;;^;`OJ QJ ^J o(hHoe  ^ `OJ QJ o(hHe  ^ `OJQJo(hHe  ^ `OJ QJ ^J o(hHoe{{^{`OJ QJ o(hHeKK^K`OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hHhhh^h`OJPJQJ^Jo(hHh88^8`OJ QJ ^J o(hHoh^`OJ QJ o(hHh  ^ `OJQJo(hHh  ^ `OJ QJ ^J o(hHohxx^x`OJ QJ o(hHhHH^H`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHecmc^c`mOJQJo(hHe^`OJ QJ ^J o(hHoepp^p`OJ QJ o(hHe@ @ ^@ `OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoePP^P`OJ QJ o(hH808^8`0o(() ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.ecmc^c`mOJQJo(hHe  ^ `OJ QJ ^J o(hHoe  ^ `OJ QJ o(hHe  ^ `OJQJo(hHe{{^{`OJ QJ ^J o(hHoeKK^K`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hHe5m5^5`mOJQJo(hHe^`OJ QJ ^J o(hHoe  ^ `OJ QJ o(hHe} } ^} `OJQJo(hHeMM^M`OJ QJ ^J o(hHoe^`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hHem^`mOJQJo(hHe^`OJ QJ ^J o(hHoepp^p`OJ QJ o(hHe@ @ ^@ `OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoePP^P`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoe  ^ `OJ QJ o(hHe} } ^} `OJQJo(hHeMM^M`OJ QJ ^J o(hHoe^`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hH80^8`0o(() ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.80^8`0o(() ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h^`CJaJhH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH.em^`mOJQJo(hHe^`OJ QJ ^J o(hHoepp^p`OJ QJ o(hHe@ @ ^@ `OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoePP^P`OJ QJ o(hHcbnb^b`nOJQJo(hHc  ^ `OJ QJ ^J o(hHoc^`OJQJo(hHc m ^ `mOJQJo(hHc} } ^} `OJ QJ ^J o(hHocMM^M`OJ QJ o(hHc^`OJQJo(hHc^`OJ QJ ^J o(hHoc^`OJ QJ o(hHem^`mOJQJo(hHe^`OJ QJ ^J o(hHoepp^p`OJ QJ o(hHe@ @ ^@ `OJQJo(hHe^`OJ QJ ^J o(hHoe^`OJ QJ o(hHe^`OJQJo(hHe^`OJ QJ ^J o(hHoePP^P`OJ QJ o(hHhp^`pOJQJo(hHh^`OJ QJ ^J o(hHohpp^p`OJ QJ o(hHh@ @ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohPP^P`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohP^P`OJ QJ o(hHN+{uycEBE )EbVeNC T*)cWh $(Q%@@ {7>1l]04$ ` [w+3 OC@t[~\9=,R0O!|a+        +                 HA                          HA        W,        0t        \O        H`        4        Xt        \O        \O        +                 N        dY        7z}        +        2&  \O     +        dn                 J~YK-^g!TWqYK-_ sn^g!TWqJ~yxcTy2AHd\r)5XbXF_t]L Ytf?Hq|RQ>$ ,6jK ~( b;NX. (<V{X V FY h }!Y!/# T#$'$n9$%r&0'E'k'(B5( )T)7*]H*K*i*j*o*v*5+v>+d+q$,u,-y"-b2-%Z-$e-Gv-Cd. 0/000O.01I1L13 3zF3L3 4#4d.4$5.5ei5r 6$6P697xc7< 8 8w%8T8 :H:C:M:&n:y:; ; ;v<<7<S<"=}=A> :>-?E?3@;C@ d@{A3A*B,Bq:CWgC7DNDP:EhEECF@OFTUFGsGnH=H8H 9HIe2I$Ic3LtL\zL!MABMYM"N'O<O18OP)DP{QzRsRS'#T4/T)CTUCUUKURVTvVyV ~VVWvWGIX\/YyJYKfZiyZE[IX[\P-\`6\T\_\B<]^U^(^0^VW^i^k^%m^O_Xa_`c'`>` a'a]abGbQc^ue5f fyf$fQ7f7^fhf;gg4CgHgrg.wgh0hYhififmimjjVNj&Zj^jPk_lk`l2m8mdPmlmnVn] n`!n8nnoqq8qfqHzqXjrs SsugsMtuLu(uOv\vNv,5wx5PxuyYyz&zZz3}zK{w{F| r|t|8};}r:~H~~[-NhEP`Xug|0e3eFsyKCw(A`iVtGDoW[s~S]+ 5uS ?AJc+,yreX]fJ MUb:fJW&gy>s .EI{Y-061WZ^x{l,tf' 2Aj+a.yJvfNs|xe 1g>AH&WN|./^>zk@ cB 9rj~l{T.5=]A$7S$1C]mbxFTEg (F:(IO\7DR!57V8gGag5 Z Ym,8 }YXp4DQN_:$N.?CSB{s18npjZ yk#|%3P1 g~0l2M(06GdXI\c9"fk#bA9yGdvm9S<s KOh ,6J"T^DJ!,qJ-Zelb\ HO wjA\BA6@F[r+&3HVj pY/7rw<'V@:O<h=BMIV$DU8?7M&ikYae4ays.D]+MO@QUVYZ$^$_$`;c;d$f$g$r$s/@^@d@jl@r@v@ @@Unknown G.[x Times New Roman5Symbol3. .Cx Arial7.*{$ Calibri= Arial Bold;*[xPHelveticaI&  Arial (W1)Arial5. .[`)TahomaK"  Arial Bold Italic?= .Cx Courier New;WingdingsA$BCambria Math"1hwRuwRutL')L')qd4  2qHP ?sG2! xx ;THE SCOTTISH GOVERNMENT HEALTH AND SOCIAL CARE DIRECTORATES iona scottConnolly C (Chris)p                    Oh+'0 4@ ` l x <THE SCOTTISH GOVERNMENT HEALTH AND SOCIAL CARE DIRECTORATES iona scottNormalConnolly C (Chris)2Microsoft Office Word@@ W>@J @J )L' ՜.+,D՜.+,P hp  00North Glasgow University Hospitals NHS Trust <THE SCOTTISH GOVERNMENT HEALTH AND SOCIAL CARE DIRECTORATES Title0 8@ _PID_HLINKSA&j'https://www.nice.org.uk/guidance/cg164*3,http://www.ncbi.nlm.nih.gov/pubmed/19249195K&http://dx.doi.org/10.1136%2Fbmj.e4505*<,http://www.ncbi.nlm.nih.gov/pubmed/227917865http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395735/./http://www.gov.scot/Resource/0049/00496709.pdf+ _Toc7510993+ _Toc7510992+ _Toc7510991+ _Toc7510990* _Toc7510989* _Toc7510988* _Toc7510987* _Toc7510986* _Toc7510985* _Toc7510984* _Toc7510983* _Toc7510982* _Toc7510981* _Toc7510980% _Toc7510979% _Toc7510978% _Toc7510977% _Toc7510976%z _Toc7510975%t _Toc7510974%n _Toc7510973%h _Toc7510972%b _Toc7510971%\ _Toc7510970$V _Toc7510969$P _Toc7510968$J _Toc7510967$D _Toc7510966$> _Toc7510965$8 _Toc7510964$2 _Toc7510963$, _Toc7510962$& _Toc7510961$  _Toc7510960' _Toc7510959' _Toc7510958' _Toc7510957' _Toc7510956' _Toc7510955  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      #Root Entry FJ~"@Data +1TableWordDocument USummaryInformation(DocumentSummaryInformation8MsoDataStoreJ~J~2SWEON5Z3DT5==2J~J~Item  PropertiesUCompObj r   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q